{"content":"<li class=\"n-box-item date-title\" data-end=\"1510635599\" data-start=\"1510549200\" data-txt=\"Monday, December 23, 2019\">Monday, November 13, 2017</li><li class=\"n-box-item sa-box-item\" data-id=\"3311726\" data-ts=\"1510620294\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ICHR\" target=\"_blank\">ICHR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3311726-ichor-holdings-names-andreson-new-chief-financial-officer\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ichor Holdings names Andreson new chief financial officer</a></h4><ul>   <li>Ichor Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/ICHR' title='Ichor Holdings, Ltd.'>ICHR</a>) has named Jeffrey Andreson as its <a href=\"https://seekingalpha.com/pr/17000704-jeff-andreson-join-ichor-chief-financial-officer\" target=\"_blank\">incoming chief financial officer</a>.</li>    <li>The move is effective Dec. 6.</li>    <li>Andreson has spent more than 25 years in financial leadership roles in the capital equipment industry and since 2014 has been CFO of Nanometrics, after a stint as CFO at Intevac.</li>    <li>He also had spent 12 years at Applied Materials.</li>    <li>Shares are <font color='green'>up 3.2%</font> after hours, and <font color='green'>gained 3.6%</font> during regular trading.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3311726\" data-linked=\"Ichor Holdings names Andreson new chief financial officer\" data-tweet=\"$ICHR - Ichor Holdings names Andreson new chief financial officer https://seekingalpha.com/news/3311726-ichor-holdings-names-andreson-new-chief-financial-officer?source=tweet\" data-url=\"https://seekingalpha.com/news/3311726-ichor-holdings-names-andreson-new-chief-financial-officer\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:44 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3311722\" data-ts=\"1510617675\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TEUM\" target=\"_blank\">TEUM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3311722-pareteumplus-13-after-significanly-narrower-loss-in-q3\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pareteum +13% after significanly narrower loss in Q3</a></h4><ul>   <li>Pareteum (NYSEMKT:<a href='https://seekingalpha.com/symbol/TEUM' title='Pareteum Corporation'>TEUM</a>) is <font color='green'>up 13.3%</font> after hours, cresting the $1/share mark in late quotes, after its <a href=\"https://seekingalpha.com/news/3311620-pareteum-beats-0_09-beats-revenue\" target=\"_blank\">Q3 loss</a> was smaller than expected and the company headed toward break-even status.</li>    <li>Revenues grew 10% Y/Y and 8% sequentially, and the company cut operating expenses 59% due to a companywide restructuring.</li>    <li>Operating loss, meanwhile, narrowed by 83% to $1.5M. Adjusted EBITDA swung to a $603,000 gain, beating an expected $90,000.</li>    <li>Backlog (36-month contractual revenue) is up to a record $114M, up 57% from Sept. 30 and marking a 393% compound annual growth rate over last Q4.</li>    <li>Revenue per employee rose to $222,139, up 44% Y/Y and up 3% from Q2.</li>    <li><a href=\"https://seekingalpha.com/pr/17000615-pareteum-announces-third-quarter-2017-financial-results\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3311722\" data-linked=\"Pareteum +13% after significanly narrower loss in Q3\" data-tweet=\"$TEUM - Pareteum +13% after significanly narrower loss in Q3 https://seekingalpha.com/news/3311722-pareteumplus-13-after-significanly-narrower-loss-in-q3?source=tweet\" data-url=\"https://seekingalpha.com/news/3311722-pareteumplus-13-after-significanly-narrower-loss-in-q3\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:01 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3311718\" data-ts=\"1510616336\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FENG\" target=\"_blank\">FENG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3311718-phoenix-new-mediaplus-6_2-after-surprise-profit-in-q3\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Phoenix New Media +6.2% after surprise profit in Q3</a></h4><ul>    <li>Phoenix New Media (NYSE:<a href='https://seekingalpha.com/symbol/FENG' title='Phoenix New Media Limited'>FENG</a>) is <font color='green'>up 6.2%</font> after hours after its <a href=\"https://seekingalpha.com/news/3311660-phoenix-new-media-beats-0_09-beats-revenue\" target=\"_blank\">Q3 report</a> beat expectations with an unexpected profit and double-digit revenue growth.</li>    <li>Revenues rose more than 18%, paced by 17% net advertising revenue gains (and 50% Y/Y gains in mobile advertising).</li>    <li>Non-GAAP net income, meanwhile, rose 38.9% to 34.4M yuan. Cost of revenues accelerated by just 2.9%.</li>    <li>Gross margin increased to 56% from 47.8%.</li>    <li>Cash and equivalents, term deposits and short-term investments and restricted cash were 1.28B yuan (about $191.9M).</li>    <li>For Q4, it's guiding to revenues of 433M-448M yuan ($65.2M-$67.5M, light of expectations for $69.1M) -- net advertising revenues of 386.2M-496.2M yuan, and paid services revenues of 46.8M-51.8M yuan.</li>    <li><a href=\"http://ir.ifeng.com/\" target=\"_blank\">Conference call</a> to come at 8 p.m. ET.</li>    <li><a href=\"https://seekingalpha.com/pr/17000680-phoenix-new-media-reports-third-quarter-2017-unaudited-financial-results\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3311718\" data-linked=\"Phoenix New Media +6.2% after surprise profit in Q3\" data-tweet=\"$FENG - Phoenix New Media +6.2% after surprise profit in Q3 https://seekingalpha.com/news/3311718-phoenix-new-mediaplus-6_2-after-surprise-profit-in-q3?source=tweet\" data-url=\"https://seekingalpha.com/news/3311718-phoenix-new-mediaplus-6_2-after-surprise-profit-in-q3\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:38 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3311703\" data-ts=\"1510613325\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3311703-after-hours-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After Hours Gainers / Losers</a></h4><ul>     <li><b>Top gainers.:</b> <a href='https://seekingalpha.com/symbol/BWLD' title='Buffalo Wild Wings, Inc.'>BWLD</a> <font color='green'>+27.8%</font>. <a href='https://seekingalpha.com/symbol/TCON' title='Tracon Pharmaceuticals'>TCON</a> <font color='green'>+19.6%</font>. <a href='https://seekingalpha.com/symbol/FENG' title='Phoenix New Media Limited'>FENG</a> <font color='green'>+4.8%</font>. <a href='https://seekingalpha.com/symbol/ERII' title='Energy Recovery, Inc.'>ERII</a> <font color='green'>+4.6%</font>. <a href='https://seekingalpha.com/symbol/AMRN' title='Amarin Corporation PLC'>AMRN</a> <font color='green'>+4.1%</font>.</li><li><b>Top losers:</b> <a href='https://seekingalpha.com/symbol/PRQR' title='ProQR Therapeutics'>PRQR</a> <font color='red'>-8.6%</font>. <a href='https://seekingalpha.com/symbol/SIRI' title='Sirius XM Holdings Inc.'>SIRI</a> <font color='red'>-1.7%</font>. <a href='https://seekingalpha.com/symbol/SAGE' title='Sage Therapeutics'>SAGE</a> <font color='red'>-1.5%</font>. <a href='https://seekingalpha.com/symbol/QRVO' title='Qorvo, Inc'>QRVO</a> <font color='red'>-1.4%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3311703\" data-linked=\"After Hours Gainers / Losers\" data-tweet=\"$BWLD $TCON $FENG - After Hours Gainers / Losers https://seekingalpha.com/news/3311703-after-hours-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3311703-after-hours-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:48 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3311690\" data-ts=\"1510611201\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SWCH\" target=\"_blank\">SWCH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3311690-switch-reports-q3-beats-in-line-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Switch reports Q3 beats, in-line guidance</a></h4><ul><li>        Switch (NYSE:<a href='https://seekingalpha.com/symbol/SWCH' title='Switch, Inc.'>SWCH</a>) reports its first earnings since the IPO. Q3 results beat revenue and EPS estimates. Full-year 2017 guidance has revenue from $372M to $380M compared to the $374.59M consensus.</li><li>               Key metrics: IPO net proceeds, $577.3M; adjusted EBITDA, $49.7M (+44% Y/Y); capital expenditures, $64.1M (-28%); churn, 0.3%; total debt, $839M.&nbsp;</li><li>               <a href=\"https://seekingalpha.com/pr/17000617-switch-announces-third-quarter-2017-financial-results\" target=\"_blank\">Press release</a>&nbsp;</li><li>Switch shares are&nbsp;<font color='red'>down 2.65%</font>&nbsp;aftermarket.&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3311618-switch-beats-0_01-beats-revenue\" target=\"_blank\">Switch beats by $0.01, beats on revenue</a> (Nov. 13)</li></ul><div class=\"tiny-share-widget\" data-id=\"3311690\" data-linked=\"Switch reports Q3 beats, in-line guidance\" data-tweet=\"$SWCH - Switch reports Q3 beats, in-line guidance https://seekingalpha.com/news/3311690-switch-reports-q3-beats-in-line-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3311690-switch-reports-q3-beats-in-line-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:13 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3311662\" data-ts=\"1510609916\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/APPN\" target=\"_blank\">APPN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3311662-appian-files-for-common-stock-offering-from-selling-shareholders\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Appian files for common stock offering from selling shareholders</a></h4><ul><li>        Appian (NASDAQ:<a href='https://seekingalpha.com/symbol/APPN' title='Appian Corp.'>APPN</a>) <a href=\"https://seekingalpha.com/pr/17000677-appian-corporation-announces-launch-follow-offering\" target=\"_blank\">files</a> for a common stock offering of 3.8M common stock shares.</li><li>               The shares come from certain selling shareholders, who have also granted the underwriters a 30-day option for up to 570K additional shares. &nbsp;&nbsp;</li><li>               Appian won&rsquo;t receive any proceeds from this offering but will bear the costs other than underwriting discounts and commissions.</li><li>               Appian shares are&nbsp;<font color='red'>down 3.66%</font>&nbsp;aftermarket.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3311662\" data-linked=\"Appian files for common stock offering from selling shareholders\" data-tweet=\"$APPN - Appian files for common stock offering from selling shareholders https://seekingalpha.com/news/3311662-appian-files-for-common-stock-offering-from-selling-shareholders?source=tweet\" data-url=\"https://seekingalpha.com/news/3311662-appian-files-for-common-stock-offering-from-selling-shareholders\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:51 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3311658\" data-ts=\"1510609732\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TCON\" target=\"_blank\">TCON</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3311658-tracons-trc102-shows-positive-action-in-early-stage-blood-cancer-study-shares-ahead-23-after\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">TRACON&#39;s TRC102 shows positive action in early-stage blood cancer study; shares ahead 23% after hours</a></h4><ul><li>Thinly traded nano cap TRACON Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/TCON' title='Tracon Pharmaceuticals'>TCON</a>) is up&nbsp;<font color='green'>23%</font>&nbsp;after hours on increased volume in response to its <a href=\"https://seekingalpha.com/pr/17000563-tracon-pharmaceuticals-announces-positive-results-phase-1-trial-trc102-fludara-patients\" target=\"_blank\">announcement </a>of positive results from a Phase 1 clinical trial assessing TRC102 (methoxyamine) and the chemo agent Fludara (fludarabine) in patients with advanced blood cancers. The data were just published in the journal <em>Oncotarget</em>.</li><li>20 patients with a range of blood cancers were enrolled, 17 with measurable disease. Each received one of five dose levels of TRC102 on the initial day of repeating three-week cycles and fludarabine on days 1 - 5.</li><li>24% of the patients with measurable disease (n=4/17) were partial responders&nbsp; while another 47% (n=8/17) had stable disease implying a 71% (n=12/17) disease control rate.</li><li>On the safety front, no dose-limiting toxicities were observed. The most frequent toxicities were hematologic and were reversible with supportive care.</li><li>TRC102 is a small molecule inhibitor of the DNA base excision pathway which causes resistance to certain chemo agents.</li></ul><div class=\"tiny-share-widget\" data-id=\"3311658\" data-linked=\"TRACON&#39;s TRC102 shows positive action in early-stage blood cancer study; shares ahead 23% after hours\" data-tweet=\"$TCON - TRACON&#39;s TRC102 shows positive action in early-stage blood cancer study; shares ahead 23% after hours https://seekingalpha.com/news/3311658-tracons-trc102-shows-positive-action-in-early-stage-blood-cancer-study-shares-ahead-23-after?source=tweet\" data-url=\"https://seekingalpha.com/news/3311658-tracons-trc102-shows-positive-action-in-early-stage-blood-cancer-study-shares-ahead-23-after\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:48 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3311650\" data-ts=\"1510609198\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ISNS\" target=\"_blank\">ISNS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3311650-image-sensing-reports-q3-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Image Sensing reports Q3 results</a></h4><ul><li>Image Sensing (NASDAQ:<a href='https://seekingalpha.com/symbol/ISNS' title='Image Sensing Systems, Inc.'>ISNS</a>): Q3 EPS of $0.17</li><li>Revenue of $3.6M (+5.9% Y/Y)</li><li>Shares <font color='green'>+24.6%</font>.</li><li><a href='https://seekingalpha.com/pr/17000571-image-sensing-systems-announces-2017-third-quarter-financial-results'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3311650\" data-linked=\"Image Sensing reports Q3 results\" data-tweet=\"$ISNS - Image Sensing reports Q3 results https://seekingalpha.com/news/3311650-image-sensing-reports-q3-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3311650-image-sensing-reports-q3-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:39 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>53&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3311648\" data-ts=\"1510609097\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BWLD\" target=\"_blank\">BWLD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3311648-buffalo-wild-wings-spikes-on-report-of-roark-capital-offer\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Buffalo Wild Wings spikes on report of Roark Capital offer</a></h4><ul><li>Buffalo Wild Wings (<a href='https://seekingalpha.com/symbol/BWLD' title='Buffalo Wild Wings, Inc.'>BWLD</a>)&nbsp;<font color='green'>spikes 22%</font>&nbsp;in AH trading on reports that Roark Capital has made an offer for the company at $150 per share.</li><li>Source: Wall Street Journal</li></ul><div class=\"tiny-share-widget\" data-id=\"3311648\" data-linked=\"Buffalo Wild Wings spikes on report of Roark Capital offer\" data-tweet=\"$BWLD - Buffalo Wild Wings spikes on report of Roark Capital offer https://seekingalpha.com/news/3311648-buffalo-wild-wings-spikes-on-report-of-roark-capital-offer?source=tweet\" data-url=\"https://seekingalpha.com/news/3311648-buffalo-wild-wings-spikes-on-report-of-roark-capital-offer\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:38 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>23&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3311643\" data-ts=\"1510608980\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MOSY\" target=\"_blank\">MOSY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3311643-mosys-beats-0_30-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">MoSys beats by $0.30, beats on revenue</a></h4><ul><li>MoSys (NASDAQ:<a href='https://seekingalpha.com/symbol/MOSY' title='MoSys, Inc.'>MOSY</a>): Q3 EPS of -$0.18 <font color='green'>beats by $0.30</font>.</li><li>Revenue of $2.45M (+56.1% Y/Y) <font color='green'>beats by $0.84M</font>.</li><li>Shares <font color='green'>+16%</font>.</li><li><a href='https://seekingalpha.com/pr/17000566-mosys-inc-reports-third-quarter-2017-financial-results'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3311643\" data-linked=\"MoSys beats by $0.30, beats on revenue\" data-tweet=\"$MOSY - MoSys beats by $0.30, beats on revenue https://seekingalpha.com/news/3311643-mosys-beats-0_30-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3311643-mosys-beats-0_30-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:36 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3311641\" data-ts=\"1510608866\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BGNE\" target=\"_blank\">BGNE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3311641-beigene-eps-of-2_54\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BeiGene EPS of $2.54</a></h4><ul><li>BeiGene (NASDAQ:<a href='https://seekingalpha.com/symbol/BGNE' title='BeiGene'>BGNE</a>): Q3 EPS of $2.54 may not be comparable to consensus of -$1.43.</li><li>Revenue of $0.22M <font color='red'>misses by $1.33M</font>.</li><li>Shares <font color='green'>+3.25%</font>.</li><li><a href=\"https://seekingalpha.com/pr/17000554-beigene-reports-third-quarter-2017-financial-results\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3311641\" data-linked=\"BeiGene EPS of $2.54\" data-tweet=\"$BGNE - BeiGene EPS of $2.54 https://seekingalpha.com/news/3311641-beigene-eps-of-2_54?source=tweet\" data-url=\"https://seekingalpha.com/news/3311641-beigene-eps-of-2_54\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:34 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3311638\" data-ts=\"1510608654\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RMBS\" target=\"_blank\">RMBS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3311638-rambus-announces-convertible-note-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Rambus announces convertible note offering</a></h4><ul><li>        Rambus (NASDAQ:<a href='https://seekingalpha.com/symbol/RMBS' title='Rambus, Inc.'>RMBS</a>) <a href=\"https://seekingalpha.com/pr/17000557-rambus-announces-proposed-150-million-convertible-senior-notes-offering\" target=\"_blank\">announces</a> proposed $150M convertible senior note offering.</li><li>               The company plans to issue initial purchasers a 13-day option to purchase up to $22.5M in additional notes.&nbsp;</li><li>               Rambus will use some of the net proceeds to pay for convertible note hedge transactions with one or more of the purchasers, affiliates, or other financial institutions to reduce potential common stock dilution. &nbsp;&nbsp;</li><li>               Rambus shares are&nbsp;<font color='red'>down 1.16%&nbsp;</font>aftermarket. &nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3311638\" data-linked=\"Rambus announces convertible note offering\" data-tweet=\"$RMBS - Rambus announces convertible note offering https://seekingalpha.com/news/3311638-rambus-announces-convertible-note-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3311638-rambus-announces-convertible-note-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:30 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3311625\" data-ts=\"1510608049\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/QUOT\" target=\"_blank\">QUOT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3311625-quotient-announces-convertible-note-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Quotient announces convertible note offering</a></h4><ul><li>        Quotient (NYSE:<a href='https://seekingalpha.com/symbol/QUOT' title='Quotient Technology Inc.'>QUOT</a>) <a href=\"https://seekingalpha.com/pr/17000559-quotient-technology-inc-announces-175-million-convertible-notes-offering\" target=\"_blank\">announces</a> a $175M convertible note offering.</li><li>           The company expects to grant initial purchasers the option to buy up to $25M in additional notes within a 13-day period of the initial issuance. </li><li> Quotient shares are&nbsp;<font color='green'>up 0.16%</font>&nbsp;aftermarket. &nbsp;&nbsp;&nbsp; </li></ul><div class=\"tiny-share-widget\" data-id=\"3311625\" data-linked=\"Quotient announces convertible note offering\" data-tweet=\"$QUOT - Quotient announces convertible note offering https://seekingalpha.com/news/3311625-quotient-announces-convertible-note-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3311625-quotient-announces-convertible-note-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:20 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3311610\" data-ts=\"1510607585\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MYO\" target=\"_blank\">MYO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3311610-myomo-advancing-secondary-equity-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Myomo advancing secondary equity offering</a></h4><ul><li>Myomo (NYSEMKT:<a href='https://seekingalpha.com/symbol/MYO' title='Myomo, Inc.'>MYO</a>) has filed a <a href=\"https://seekingalpha.com/pr/17000562-myomo-inc-files-registration-statement-proposed-follow-offering\" target=\"_blank\">registration statement </a>with the SEC for a proposed follow-on offering of common stock and warrants. Price, volume and terms have yet to be released.</li></ul><div class=\"tiny-share-widget\" data-id=\"3311610\" data-linked=\"Myomo advancing secondary equity offering\" data-tweet=\"$MYO - Myomo advancing secondary equity offering https://seekingalpha.com/news/3311610-myomo-advancing-secondary-equity-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3311610-myomo-advancing-secondary-equity-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:13 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3311600\" data-ts=\"1510607223\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PRQR\" target=\"_blank\">PRQR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3311600-proqr-readies-equity-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ProQR readies equity offering</a></h4><ul><li>ProQR Therapeutics N.V. (NASDAQ:<a href='https://seekingalpha.com/symbol/PRQR' title='ProQR Therapeutics'>PRQR</a>) <a href=\"https://seekingalpha.com/pr/17000528-proqr-announces-proposed-public-offering-ordinary-shares\" target=\"_blank\">launches </a>a public offering of ordinary shares. Price, volume and terms have yet to be released.</li><li>Net proceeds will fund clinical trials, R&amp;D, working capital and general corporate purposes.</li></ul><div class=\"tiny-share-widget\" data-id=\"3311600\" data-linked=\"ProQR readies equity offering\" data-tweet=\"$PRQR - ProQR readies equity offering https://seekingalpha.com/news/3311600-proqr-readies-equity-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3311600-proqr-readies-equity-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:07 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3311595\" data-ts=\"1510607046\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SAGE\" target=\"_blank\">SAGE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3311595-sage-readies-300m-stock-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sage readies $300M stock offering</a></h4><ul><li>Sage Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/SAGE' title='Sage Therapeutics'>SAGE</a>) <a href=\"https://seekingalpha.com/pr/17000537-sage-therapeutics-announces-proposed-public-offering-common-stock\" target=\"_blank\">launches </a>a public offering of $300M of common stock. Price, volume and terms have yet to be announced.</li></ul><div class=\"tiny-share-widget\" data-id=\"3311595\" data-linked=\"Sage readies $300M stock offering\" data-tweet=\"$SAGE - Sage readies $300M stock offering https://seekingalpha.com/news/3311595-sage-readies-300m-stock-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3311595-sage-readies-300m-stock-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:04 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3311585\" data-ts=\"1510606703\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IMMU\" target=\"_blank\">IMMU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3311585-wells-defends-immunomedics-19-selloff-buying-opportunity\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Wells defends Immunomedics, 19% selloff a &quot;buying opportunity&quot;</a></h4><ul><li>Wells Fargo's Jim Birchenough says today's negative action for Immunomedics (<a href='https://seekingalpha.com/symbol/IMMU' title='Immunomedics, Inc.'>IMMU</a> <font color='red'>-19.1%</font>) is a \"buying opportunity\" after seeing an overview of abstract data on lead candidate IMMU-132 (sacituzumab govitecan), adding that the results support accelerated approval (OUTPERFORM/$14).</li><li>Source: Bloomberg</li><li>Investors appear concerned about the company's lack of disclosure of data to be <a href=\"https://seekingalpha.com/pr/17000057-immunomedics-announces-presentations-investor-event-2017-san-antonio-breast-cancer-symposium\" target=\"_blank\">presented</a> at the San Antonio Breast Cancer Symposium in early December. One abstract (#1727) will detail Phase 2 results in treatment-resistant metastatic triple negative breast cancer. The objective response rate was 34% as determined by local radiologist assessment but the results from the independent central blinded review will be presented at the meeting.</li></ul><div class=\"tiny-share-widget\" data-id=\"3311585\" data-linked=\"Wells defends Immunomedics, 19% selloff a &quot;buying opportunity&quot;\" data-tweet=\"$IMMU - Wells defends Immunomedics, 19% selloff a &quot;buying opportunity&quot; https://seekingalpha.com/news/3311585-wells-defends-immunomedics-19-selloff-buying-opportunity?source=tweet\" data-url=\"https://seekingalpha.com/news/3311585-wells-defends-immunomedics-19-selloff-buying-opportunity\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:58 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3311579\" data-ts=\"1510604600\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MDSO\" target=\"_blank\">MDSO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3311579-dougherty-company-upgrades-medidata-on-reduced-risks\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Dougherty &amp; Company upgrades Medidata on reduced risks</a></h4><ul><li>        Dougherty &amp; Company<a href=\"http://www.briefing.com/DisplayArticle/ArticlePopup.aspx?ArticleId=IN20171113122359MDSO\" target=\"_blank\"> upgrades</a> Medidata (NASDAQ:<a href='https://seekingalpha.com/symbol/MDSO' title='Medidata Solutions, Inc.'>MDSO</a>) from Neutral to Buy with a $75 price target.</li><li>               The firm says the company&rsquo;s Analyst Day and associated diligence showed previously outlined risks are reduced.&nbsp;</li><li>               The risks were valuation, disruption in CRO channel customers, and the long-term threat of a new competitor. &nbsp;&nbsp;</li><li>               Medidata shares are&nbsp;<font color='green'>up 1.31%</font>&nbsp;to $66.55. &nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3311579\" data-linked=\"Dougherty &amp; Company upgrades Medidata on reduced risks\" data-tweet=\"$MDSO - Dougherty &amp; Company upgrades Medidata on reduced risks https://seekingalpha.com/news/3311579-dougherty-company-upgrades-medidata-on-reduced-risks?source=tweet\" data-url=\"https://seekingalpha.com/news/3311579-dougherty-company-upgrades-medidata-on-reduced-risks\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:23 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3311577\" data-ts=\"1510604015\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/INFN\" target=\"_blank\">INFN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3311577-infinera-up-6-ceo-buys-dip\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Infinera up 6% as CEO buys the dip</a></h4><ul><li>CEO Thomas Fallon today<a href=\"https://seekingalpha.com/filing/3763102\" target=\"_blank\"> bought 100K shares</a> of company stock at $6.33 each, bringing his stake to nearly 1.3M shares.</li><li><a href='https://seekingalpha.com/symbol/INFN' title='Infinera Corporation'>INFN</a>&nbsp;<font color='green'>+6.2%</font>&nbsp;to $6.75</li><li>Previously: <a href=\"https://seekingalpha.com/news/3310604-infinera-minus-12_7-percent-guidance-downgrade-mkm\" target=\"_blank\">Infinera -12.7% after guidance, downgrade from MKM</a> (Nov. 9)</li></ul><div class=\"tiny-share-widget\" data-id=\"3311577\" data-linked=\"Infinera up 6% as CEO buys the dip\" data-tweet=\"$INFN - Infinera up 6% as CEO buys the dip https://seekingalpha.com/news/3311577-infinera-up-6-ceo-buys-dip?source=tweet\" data-url=\"https://seekingalpha.com/news/3311577-infinera-up-6-ceo-buys-dip\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:13 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3311571\" data-ts=\"1510602726\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3311571-energy-materials-top-gainers-losers-of-2-50-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energy/Materials - Top Gainers / Losers as of 2:50 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/HK' title='Halcon Resources Corporation'>HK</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/NAK' title='Northern Dynasty Minerals Ltd'>NAK</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/CDXC' title='ChromaDex Inc.'>CDXC</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/OSN' title='Ossen Innovation Co., Ltd.'>OSN</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/USAU' title='U.S. Gold Corp.'>USAU</a> <font color='green'>+7%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/KLDX' title='Klondex Mines Ltd.'>KLDX</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/KEG' title='Key Energy Services, Inc.'>KEG</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/SNES' title='SenesTech'>SNES</a> <font color='red'>-9%</font>. PGH <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/WG' title='Willbros Group, Inc.'>WG</a> <font color='red'>-8%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3311571\" data-linked=\"Energy/Materials - Top Gainers / Losers as of 2:50 pm\" data-tweet=\"$HKRS $NAK $CDXC - Energy/Materials - Top Gainers / Losers as of 2:50 pm https://seekingalpha.com/news/3311571-energy-materials-top-gainers-losers-of-2-50-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3311571-energy-materials-top-gainers-losers-of-2-50-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:52 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3311570\" data-ts=\"1510602571\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/QCOM\" target=\"_blank\">QCOM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3311570-analyst-takes-higher-bid-likely-in-cards-for-broadcom-qualcomm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Analyst takes: Higher bid likely in cards for Broadcom-Qualcomm</a></h4><ul>   <li>With Qualcomm's (<a href=\"http://seekingalpha.com/symbol/QCOM\" target=\"_blank\">QCOM</a> <font color='green'>+2.9%</font>) <a href=\"https://seekingalpha.com/news/3311444-qualcomm-rejects-takeover-bid-broadcom-value-regulatory-concern\" target=\"_blank\">rejection of a $105B buyout</a> from Broadcom (<a href=\"http://seekingalpha.com/symbol/AVGO\" target=\"_blank\">AVGO</a> <font color='red'>-0.1%</font>) officially on the books (and a <a href=\"https://seekingalpha.com/news/3311511-broadcom-rejection-fully-committed-qualcomm-buyout\" target=\"_blank\">determined response from Broadcom</a>), analyst consensus seems to be settling around the arrival of a higher bid (but how much higher?) than the current $70/share offer.</li>    <li>RBC thinks the price may be right at $80/share, though it may go to a proxy battle in which Qualcomm would be pressed to outline a path to creating value if it wants to stay independent.</li>    <li>The $80 <a href=\"http://www.barrons.com/articles/qualcomm-broadcom-to-bid-higher-say-bernstein-canaccord-may-go-hostile-1510591791\" target=\"_blank\">sounds right to Bernstein's Stacy Rasgon</a> as well: \"We aren't that far away from something that might seem more palatable ($80-ish?)&rdquo; Rasgon reiterated an Outperform rating on Broadcom and Market Perform on Qualcomm.</li>    <li>Qualcomm's rejection is \"not representative of them necessarily 'digging in,' but it also is relatively bereft of any concrete plan beyond 'trust us' (which we suspect shareholders might not find hugely compelling),\" Rasgon writes.</li>    <li>And Canaccord has boosted its price target for Qualcomm to $83 from $76, expecting a higher bid. Qualcomm is trading at $66.46 now.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3311570\" data-linked=\"Analyst takes: Higher bid likely in cards for Broadcom-Qualcomm\" data-tweet=\"$QCOM $QCOM $AVGO - Analyst takes: Higher bid likely in cards for Broadcom-Qualcomm https://seekingalpha.com/news/3311570-analyst-takes-higher-bid-likely-in-cards-for-broadcom-qualcomm?source=tweet\" data-url=\"https://seekingalpha.com/news/3311570-analyst-takes-higher-bid-likely-in-cards-for-broadcom-qualcomm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:49 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>28&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3311568\" data-ts=\"1510602283\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/INTC\" target=\"_blank\">INTC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3311568-intel-and-micron-complete-fab-expansion-micron-announces-new-nvdimm-product\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Intel and Micron complete fab expansion; Micron announces new NVDIMM product</a></h4><ul><li>        Intel (NASDAQ:<a href='https://seekingalpha.com/symbol/INTC' title='Intel Corporation'>INTC</a>) and Micron (NASDAQ:<a href='https://seekingalpha.com/symbol/MU' title='Micron Technology Inc.'>MU</a>) <a href=\"https://newsroom.intel.com/news/intel-micron-expand-3d-xpoint-manufacturing-capacity-im-flash-fab-expansion/?utm_source=feedburner&amp;utm_medium=feed&amp;utm_campaign=Feed%3A+IntelNewsroom+%28Intel+Newsroom%29\" target=\"_blank\">announce</a> the completion of the IM Flash fab expansion in Lehi, Utah.</li><li>               The fab expansion will produce 3D XPoint, a type of memory media used in Intel&rsquo;s Optane technology.&nbsp;&nbsp;</li><li>        Micron separately <a href=\"https://seekingalpha.com/pr/16999927-micron-advances-persistent-memory-32gb-nvdimm\" target=\"_blank\">announces</a> a new 32GB NVDIMM-N with twice the capacity of existing products.</li><li>                  Micron says deploying NVDIMMs can improve server configuration performance benefits by up to 400% compared to traditional far storage.    </li><li>Micron shares are&nbsp;<font color='green'>up 2.08%</font>.&nbsp;</li><li>Intel shares are&nbsp;<font color='green'>up 0.47%</font>.&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3311434-global-dram-market-16-percent-q3\" target=\"_blank\">Global DRAM market up 16% in Q3</a> (Nov. 13)</li></ul><div class=\"tiny-share-widget\" data-id=\"3311568\" data-linked=\"Intel and Micron complete fab expansion; Micron announces new NVDIMM product\" data-tweet=\"$INTC $INTC $MU - Intel and Micron complete fab expansion; Micron announces new NVDIMM product https://seekingalpha.com/news/3311568-intel-and-micron-complete-fab-expansion-micron-announces-new-nvdimm-product?source=tweet\" data-url=\"https://seekingalpha.com/news/3311568-intel-and-micron-complete-fab-expansion-micron-announces-new-nvdimm-product\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:44 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>33&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3311565\" data-ts=\"1510601513\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ROKU\" target=\"_blank\">ROKU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3311565-rokuplus-32-amid-black-friday-promos-philips-tv-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Roku +32% amid Black Friday promos, Philips TV deal</a></h4><ul>   <li>Roku (NASDAQ:<a href='https://seekingalpha.com/symbol/ROKU' title='Roku Inc.'>ROKU</a>) is <font color='green'>up 32.1%</font>, continuing a string of hot days after its initial earnings release last Wednesday, amid a slew of small news items it's making today.</li>    <li>Funai Electric, a Philips brand licensee, has <a href=\"https://seekingalpha.com/pr/16999919-funai-electric-joins-roku-tv-licensing-program\" target=\"_blank\">joined the Roku TV licensing program</a> and will build smart Philips TVs that run the Roku OS.</li>    <li>Roku's <a href=\"https://seekingalpha.com/pr/16999928-roku-offers-20-new-roku-streaming-stick-black-friday-weekend\" target=\"_blank\">Black Friday deal</a> is a \"deep\" discount on its Streaming Stick Plus device, which it's marking down to $50 &#40;MSRP&#41; from $70. The company's Roku Express Plus (a Wal-Mart exclusive) will also get a Thanksgiving markdown.</li>    <li>Along with that deal, buyers will be eligible for a free month of any DirecTV Now package.</li>    <li>And Eros International (<a href=\"http://seekingalpha.com/symbol/EROS\" target=\"_blank\">EROS</a> <font color='red'>-0.4%</font>) has <a href=\"https://seekingalpha.com/pr/17000015-eros-now-announces-association-roku\" target=\"_blank\">partnered with Roku</a> to include its Eros Now streaming service.</li>    <li>Roku shares have <font color='green'>risen 130%</font> since the company <a href=\"https://seekingalpha.com/news/3310108-roku-vaults-26-percent-first-revenue-report-sails-bar\" target=\"_blank\">easily surpassed expectations</a> in earnings last week.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3311565\" data-linked=\"Roku +32% amid Black Friday promos, Philips TV deal\" data-tweet=\"$ROKU $ROKU $EROS - Roku +32% amid Black Friday promos, Philips TV deal https://seekingalpha.com/news/3311565-rokuplus-32-amid-black-friday-promos-philips-tv-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3311565-rokuplus-32-amid-black-friday-promos-philips-tv-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:31 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>35&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3311569\" data-ts=\"1510601154\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ASUR\" target=\"_blank\">ASUR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3311569-asure-softwareplus-11-after-q3-revenue-beat-reaffirmed-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Asure Software +11% after Q3 revenue beat, reaffirmed guidance</a></h4><ul>     <li>Asure Software (<a href='https://seekingalpha.com/symbol/ASUR' title='Asure Software, Inc.'>ASUR</a> <font color='green'>+10.3%</font>) shares are&nbsp;<font color='green'>up 11%</font>&nbsp;after a Q3 results that meet EPS estimates &amp; beat revenue estimates.</li>     <li>FY17 guidance: revenue - $54.25M - $56.25M (consensus $54.78M);&nbsp;Non-GAAP EBITDA, excluding one-time items, of between $12.2M - $13.5M; Non-GAAP net income per share of between $0.50 - $0.56 (consensus $0.53).</li>     <li>FY18, Asure reaffirmed its objective to reach double-digit organic revenue growth with multiple &ldquo;tuck-in&rdquo; acquisitions each of ~$2.0M of revenue and a purchase price of ~ 2x revenue. In addition, Asure seeks to reach between $70.0M - $80.0M of revenue in 2018, with non-GAAP EBITDA, excluding one-time items, of between $16.0M - $20.0M.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3311433-asure-software-eps-line-beats-revenue\" target=\"_blank\">Asure Software EPS in-line, beats on revenue</a> (Nov. 13)</li><li><a href=\"https://seekingalpha.com/pr/16999872-asure-software-reports-record-third-quarter-2017-revenue-reaffirms-guidance-full-year\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3311569\" data-linked=\"Asure Software +11% after Q3 revenue beat, reaffirmed guidance\" data-tweet=\"$ASUR - Asure Software +11% after Q3 revenue beat, reaffirmed guidance https://seekingalpha.com/news/3311569-asure-softwareplus-11-after-q3-revenue-beat-reaffirmed-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3311569-asure-softwareplus-11-after-q3-revenue-beat-reaffirmed-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:25 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3311562\" data-ts=\"1510600749\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GE\" target=\"_blank\">GE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3311562-ge-selloff-reachesminus-8-new-era-starts-investor-pessimism\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">GE selloff reaches -8% as &#39;new era&#39; starts with investor pessimism</a></h4><ul>     <li>General Electric (<a href='https://seekingalpha.com/symbol/GE' title='General Electric'>GE</a> <font color='red'>-7.8%</font>) sinks in what is shaping up as the stock's <a href=\"https://www.cnbc.com/2017/11/13/ge-announces-broad-restructuring-to-keep-health-care-aviation-and-energy-units.html\" target=\"_blank\">worst day since April 2009</a>, as investors question whether the <a href=\"https://seekingalpha.com/news/3311453-live-ges-investor-update-webcast\" target=\"_blank\">plans outlined this morning</a> by CEO&nbsp;John Flannery will be <a href=\"https://www.bloomberg.com/news/articles/2017-11-13/ge-cuts-dividend-in-half-as-new-ceo-battles-deepening-slump\" target=\"_blank\">enough to turn around the company</a>.</li>     <li>&ldquo;There is no doubt that the plan outlined today marks a new era for GE,&rdquo; says RBC analyst Deane Dray. &ldquo;That said, does it go far enough?&rdquo;</li>     <li>&ldquo;We see this as a <a href=\"https://www.marketwatch.com/story/ges-stock-falls-to-5-12-year-low-as-new-sec-rule-to-cut-profit-estimate-by-21-billion-2017-11-13\" target=\"_blank\">multiyear transition</a>,&rdquo; says CFRA's Jim Corridore. &ldquo;We would wait for traction on actions before adding to positions.&rdquo;</li>     <li>&ldquo;By the numbers, we see a core operating performance that is <a href=\"http://www.reuters.com/article/us-ge-review/ge-to-shrink-investors-worry-it-will-be-less-profitable-idUSKBN1DD0H3\" target=\"_blank\">below plan</a>, and, currently, a consensus expectations curve that we think remains too high,&rdquo; according to Stephen Tusa at J.P. Morgan.</li>     <li><a href=\"http://www.barrons.com/articles/if-complexity-hurt-general-electric-why-is-it-still-so-darned-complicated-1510596444\" target=\"_blank\">GE is still too complicated</a>, according to Melius Research's Scott Davis, who adds that \"it's not clear why a bigger spinoff didn&rsquo;t make the cut. Flannery noted that 'complexity has hurt us' [but] the 'new' GE still seems pretty complicated.\"</li></ul><div class=\"tiny-share-widget\" data-id=\"3311562\" data-linked=\"GE selloff reaches -8% as &#39;new era&#39; starts with investor pessimism\" data-tweet=\"$GE - GE selloff reaches -8% as &#39;new era&#39; starts with investor pessimism https://seekingalpha.com/news/3311562-ge-selloff-reachesminus-8-new-era-starts-investor-pessimism?source=tweet\" data-url=\"https://seekingalpha.com/news/3311562-ge-selloff-reachesminus-8-new-era-starts-investor-pessimism\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:19 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>106&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3311561\" data-ts=\"1510600169\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMZN\" target=\"_blank\">AMZN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3311561-amazon-announces-original-series-based-on-the-lord-of-rings\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Amazon announces original series based on &#39;The Lord of the Rings&#39;</a></h4><ul><li>        Amazon (NASDAQ:<a href='https://seekingalpha.com/symbol/AMZN' title='Amazon.com, Inc.'>AMZN</a>) <a href=\"http://phx.corporate-ir.net/phoenix.zhtml?c=176060&amp;p=RssLanding&amp;cat=news&amp;id=2316587\" target=\"_blank\">announces</a> multi-season global television rights to J.R.R. Tolkien&rsquo;s <i>The Lord of the Rings</i>.</li><li>                  The adaptation will &ldquo;explore new storylines&rdquo; taking place before <i>The Fellowship of the Ring</i>.    </li><li>                  Amazon Studios, the Tolkien Estate and Trust, publisher HarperCollins, and Warner Bros&rsquo; division New Line Cinema will produce the Amazon Prime Original.    </li><li>                  The deal includes the option for an additional spin-off series.    </li><li>Amazon shares are&nbsp;<font color='green'>up 1.19%</font>.&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3311550-information-amazon-web-services-planning-ai-push\" target=\"_blank\">The Information: Amazon Web Services planning AI push</a> (Nov. 13)</li></ul><div class=\"tiny-share-widget\" data-id=\"3311561\" data-linked=\"Amazon announces original series based on &#39;The Lord of the Rings&#39;\" data-tweet=\"$AMZN - Amazon announces original series based on &#39;The Lord of the Rings&#39; https://seekingalpha.com/news/3311561-amazon-announces-original-series-based-on-the-lord-of-rings?source=tweet\" data-url=\"https://seekingalpha.com/news/3311561-amazon-announces-original-series-based-on-the-lord-of-rings\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:09 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>21&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3311556\" data-ts=\"1510599416\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3311556-technology-top-gainers-losers-of-1-55-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Technology - Top Gainers / Losers as of 1:55 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/CCIH' title='ChinaCache International'>CCIH</a> <font color='green'>+16%</font>. <a href='https://seekingalpha.com/symbol/CNIT-OLD' title='China Information Technology'>CNIT-OLD</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/ENPH' title='Enphase Energy Inc.'>ENPH</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/ASUR' title='Asure Software, Inc.'>ASUR</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/GDS' title='GDS Holdings'>GDS</a> <font color='green'>+8%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/DTRM' title='Determine, Inc.'>OTC:DTRM</a> <font color='red'>-14%</font>. <a href='https://seekingalpha.com/symbol/QTM-OLD' title='Quantum Corporation'>QTM-OLD</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/SPI' title='SPI Energy Co., Ltd.'>SPI</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/APDN' title='Applied DNA Sciences, Inc.'>APDN</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/KONE' title='Kingtone Wirelessinfo Solution Holding Ltd'>KONE</a> <font color='red'>-8%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3311556\" data-linked=\"Technology - Top Gainers / Losers as of 1:55 pm\" data-tweet=\"$CCIH $CNIT-OLD $ENPH - Technology - Top Gainers / Losers as of 1:55 pm https://seekingalpha.com/news/3311556-technology-top-gainers-losers-of-1-55-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3311556-technology-top-gainers-losers-of-1-55-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:56 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3311551\" data-ts=\"1510599047\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PHIO\" target=\"_blank\">PHIO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3311551-rxi-pharma-teams-up-gustave-roussy-to-explore-sd-rxrna-platform-in-cancer-shares-up-4\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">RXi Pharma teams up with Gustave Roussy to explore sd-rxRNA platform in cancer; shares up 4%</a></h4><ul><li>Nano cap RXi Pharmaceuticals (RXII <font color='green'>+4.3%</font>) perks up on light volume in response to its <a href=\"https://seekingalpha.com/pr/16999556-rxi-pharmaceuticals-gustave-roussy-announce-research-collaboration\" target=\"_blank\">announced </a>collaborative research agreement with European cancer center Gustave Roussy aimed at evaluating potential cancer treatments based on its <a href=\"http://www.rxipharma.com/technology/sd-rxrna/\" target=\"_blank\">sd-rxRNA</a> platform.</li><li>The agreement covers research to design and evaluate sd-rxRNA compounds in a human tumor xenograft model.</li><li>Financial terms are not disclosed.</li></ul><div class=\"tiny-share-widget\" data-id=\"3311551\" data-linked=\"RXi Pharma teams up with Gustave Roussy to explore sd-rxRNA platform in cancer; shares up 4%\" data-tweet=\"$PHIO - RXi Pharma teams up with Gustave Roussy to explore sd-rxRNA platform in cancer; shares up 4% https://seekingalpha.com/news/3311551-rxi-pharma-teams-up-gustave-roussy-to-explore-sd-rxrna-platform-in-cancer-shares-up-4?source=tweet\" data-url=\"https://seekingalpha.com/news/3311551-rxi-pharma-teams-up-gustave-roussy-to-explore-sd-rxrna-platform-in-cancer-shares-up-4\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:50 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3311552\" data-ts=\"1510599002\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VIA\" target=\"_blank\">VIA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3311552-thor-latest-series-film-holds-onto-box-office-lead\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">More &#39;Thor&#39;: Latest series film holds onto box-office lead</a></h4><ul>   <li><i>Thor: Ragnarok</i> (<a href=\"http://seekingalpha.com/symbol/DIS\" target=\"_blank\">DIS</a> <font color='red'>-0.4%</font>) repeated at the top of the box-office charts over the weekend with a solid $56.6M follow-up.</li>    <li>That was good enough to out-gross two newcomers, <i>Daddy's Home 2</i> (<a href='https://seekingalpha.com/symbol/VIA' title='Viacom Inc.'>VIA</a> <font color='red'>-2.6%</font>, <a href='https://seekingalpha.com/symbol/VIAB' title='Viacom Inc.'>VIAB</a> <font color='red'>-2.3%</font>) with $30M and a new version of <i>Murder on the Orient Express</i> (<a href='https://seekingalpha.com/symbol/FOX' title='Twenty-First Century Fox, Inc.'>FOX</a> <font color='red'>-1.5%</font>, <a href='https://seekingalpha.com/symbol/FOXA' title='Twenty-First Century Fox, Inc.'>FOXA</a> <font color='red'>-1.7%</font>) with $28.2M.</li>    <li>Other holdovers moved down a couple of spots to make room: <i>A Bad Moms Christmas</i> drew $11.5M for the No. 4 spot, and a Halloween pair from Lions Gate (<a href='https://seekingalpha.com/symbol/LGF.A' title='Lions Gate Entertainment Corp.'>LGF.A</a> <font color='red'>-1.7%</font>, <a href='https://seekingalpha.com/symbol/LGF.B' title='Lions Gate Entertainment Corp.'>LGF.B</a> <font color='red'>-1.3%</font>) -- <i>Jigsaw</i> and <i>Tyler Perry's Boo 2! A Madea Halloween</i> were still eking out scares with $3.4M and $2.1M respectively.</li>    <li>The latest <i>Thor</i> film has crested $211M in cumulative domestic grosses, and hit $650M worldwide, surpassing <i>Thor: The Dark World</i> to become the best-performing film in the series.</li>    <li>That also makes it the 12th best performer in the Marvel Cinematic Universe, according to Box Office Mojo; it's about $21M behind <i>Doctor Strange</i> on the domestic chart, and <i>Doctor Strange</i> drew $678M worldwide.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3311552\" data-linked=\"More &#39;Thor&#39;: Latest series film holds onto box-office lead\" data-tweet=\"$VIA $VIA $VIAB - More &#39;Thor&#39;: Latest series film holds onto box-office lead https://seekingalpha.com/news/3311552-thor-latest-series-film-holds-onto-box-office-lead?source=tweet\" data-url=\"https://seekingalpha.com/news/3311552-thor-latest-series-film-holds-onto-box-office-lead\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:50 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3311549\" data-ts=\"1510598454\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WETF\" target=\"_blank\">WETF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3311549-wisdomtree-down-5-after-purchase-sell-side-lukewarm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">WisdomTree down more than 5% after purchase; sell-side lukewarm</a></h4><ul><li>Number one, the deal isn't particularly cheap, says Jefferies'&nbsp;Surinder Thind, with a purchase price of roughly 16x EBITDA.</li><li>Number two, WisdomTree (<a href='https://seekingalpha.com/symbol/WETF' title='WisdomTree Investments, Inc.'>WETF</a> <font color='red'>-5.4%</font>) is cutting the dividend and taking on debt for the first time.</li><li>Goldman's Alexander Blostein supplies point number three: The purchase lowers the near-term chances of WisdomTree being an acquisition target.</li><li>Source: Bloomberg</li><li>Previously: <a href=\"https://seekingalpha.com/news/3311371-wisdomtree-scales-europe-acquisition\" target=\"_blank\">WisdomTree scales up in Europe with acquisition</a> (Nov. 13)</li></ul><div class=\"tiny-share-widget\" data-id=\"3311549\" data-linked=\"WisdomTree down more than 5% after purchase; sell-side lukewarm\" data-tweet=\"$WETF - WisdomTree down more than 5% after purchase; sell-side lukewarm https://seekingalpha.com/news/3311549-wisdomtree-down-5-after-purchase-sell-side-lukewarm?source=tweet\" data-url=\"https://seekingalpha.com/news/3311549-wisdomtree-down-5-after-purchase-sell-side-lukewarm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:40 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3311543\" data-ts=\"1510598097\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SNDX\" target=\"_blank\">SNDX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3311543-syndax-pharma-reports-study-results-support-treatment-benefit-of-entinostat-investors-unmoved\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Syndax Pharma reports study results that support treatment benefit of entinostat,  investors unmoved after Nektar data, shares down 11%</a></h4><ul><li>Thinly traded micro cap Syndax Pharmaceuticals (<a href='https://seekingalpha.com/symbol/SNDX' title='Syndax Pharmaceuticals, Inc.'>SNDX</a> <font color='red'>-10.9%</font>) slumps on 50% higher volume, albeit on turnover of only 153K shares, on the heels of its <a href=\"https://seekingalpha.com/pr/16999252-syndax-pharmaceuticals-announces-presentation-data-immuno-oncology-clinical-trials-society\" target=\"_blank\">announcement </a>of results from an open-label Phase 1b/2 study, ENCORE 601, evaluating the combination of entinostat and Merck's (<a href='https://seekingalpha.com/symbol/MRK' title='Merck & Co Inc.'>MRK</a> <font color='red'>-0.4%</font>) KEYTRUDA (pembrolizumab) in patients with non-small cell lung cancer &#40;NSCLC&#41;, melanoma and colorectal cancer &#40;CRC&#41;. The data were presented at the SITC Annual Meeting in National Harbor, MD.</li><li>The overall response rate in NSCLC patients who progressed after anti-PD-1 or anti-PD-L1 therapy was 10% and 24% in NSCLC patients who had not been previously treated with a PD-1 or PD-L1 inhibitor.</li><li>Across both cohorts, the responders with known PD-&#40;L&#41;1 expression levels were either low (1-49%) or negative (&lt;1%) expressors.</li><li>The combination of Nektar Therapeutics' (<a href='https://seekingalpha.com/symbol/NKTR' title='Nektar Therapeutics'>NKTR</a> <font color='green'>+15.6%</font>) NKTR-214 and BMY's Opdivo (nivolumab) produced a 75% (n=3/4) response rate in NSCLC patients who did not express PD-L1 and had progressed after chemo.</li><li>The study is ongoing. A decision on advancing the colorectal cancer cohort into Phase 2 will be made in H1 2018 (the lung cancer and melanoma cohorts have already been advanced).</li><li><a href=\"http://www.syndax.com/pipeline/entinostat/\" target=\"_blank\">Entinostat&nbsp;</a>is a small molecule that inhibits an enzyme class called histone deacetylases (HDACs), specifically Class 1 HDACs which play a key role in modulating immuno-suppressive cells called myeloid-derived suppressor cells (MDSCs) and regulatory T cells. The company says entinostat has therapeutic potential in a range of cancers when used in combination with immune checkpoint inhibitors (like Keytruda).</li><li>Previously: <a href=\"https://seekingalpha.com/news/3311468-combination-opdivo-nektars-nktrminus-214-show-positive-effect-advanced-lung-cancer-phase-1-2\" target=\"_blank\">Combination of Opdivo and Nektar's NKTR-214 show positive effect in advanced lung cancer in Phase 1/2 study</a> (Nov. 13)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3311499-nektars-gain-calitheras-pain-opdivo-combo-treatments-shares-15-percent\" target=\"_blank\">Nektar's gain Calithera's pain on Opdivo combo treatments; shares down 15%</a> (Nov. 13)</li></ul><div class=\"tiny-share-widget\" data-id=\"3311543\" data-linked=\"Syndax Pharma reports study results that support treatment benefit of entinostat,  investors unmoved after Nektar data, shares down 11%\" data-tweet=\"$SNDX $SNDX $MRK - Syndax Pharma reports study results that support treatment benefit of entinostat, investors unmoved after Nektar data, shares down 11% https://seekingalpha.com/news/3311543-syndax-pharma-reports-study-results-support-treatment-benefit-of-entinostat-investors-unmoved?source=tweet\" data-url=\"https://seekingalpha.com/news/3311543-syndax-pharma-reports-study-results-support-treatment-benefit-of-entinostat-investors-unmoved\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:34 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3311547\" data-ts=\"1510597598\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CABO\" target=\"_blank\">CABO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3311547-cable-oneminus-1_8-jpmorgan-cuts-to-underweight\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cable One -1.8% as JPMorgan cuts to Underweight</a></h4><ul>   <li>Cable One (NYSE:<a href='https://seekingalpha.com/symbol/CABO' title='Cable One, Inc.'>CABO</a>) is <font color='red'>off 1.8%</font> after being cut to Underweight by JPMorgan, which calls it \"more than fully valued.\"</li>    <li>Even with growth lower than comparable firms, the company trades at an enterprise value/2018 EBITDA multiple of 10, vs. peers' 8-10, analyst Philip Cusick notes (h/t Bloomberg).</li>    <li>The company's facing less attractive demographics in its markets and has limited ability to raise prices without a negative effect on subscribe growth, the firm says.</li>    <li>JPMorgan has trimmed its price target to $685 from $715, implying just 2% upside from today's lower price.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3311547\" data-linked=\"Cable One -1.8% as JPMorgan cuts to Underweight\" data-tweet=\"$CABO - Cable One -1.8% as JPMorgan cuts to Underweight https://seekingalpha.com/news/3311547-cable-oneminus-1_8-jpmorgan-cuts-to-underweight?source=tweet\" data-url=\"https://seekingalpha.com/news/3311547-cable-oneminus-1_8-jpmorgan-cuts-to-underweight\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:26 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3311541\" data-ts=\"1510596394\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SNMSF\" target=\"_blank\">SNMSF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3311541-investors-take-spin-spin-master\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Investors take a spin with Spin Master</a></h4><ul> <li>Shares of Spin Master Corp (<a href='https://seekingalpha.com/symbol/SNMSF' title='SPIN MASTER CORP'>OTC:SNMSF</a>) are <font color='green'>up 2.4%</font> in Toronto trading as the impact of a potential tie-up between Hasbro and Mattel is digested.</li> <li>Positive comments from the Wells Fargo toy team may be helping to lift sentiment as well.</li> <li>\"We believe Spin Master could be an OEM that may garner more license share from IP studios over time post a HAS/MAT merger,\" <a href=\"http://www.barrons.com/articles/mattel-party-like-its-1987-1510591225\" target=\"_blank\">reasons</a> WF.</li> <li>Spin Master is up 54% YTD</li> </ul><div class=\"tiny-share-widget\" data-id=\"3311541\" data-linked=\"Investors take a spin with Spin Master\" data-tweet=\"$SNMSF - Investors take a spin with Spin Master https://seekingalpha.com/news/3311541-investors-take-spin-spin-master?source=tweet\" data-url=\"https://seekingalpha.com/news/3311541-investors-take-spin-spin-master\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:06 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3311540\" data-ts=\"1510596164\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ADSK\" target=\"_blank\">ADSK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3311540-guggenheim-upgrades-autodesk-raises-price-target\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Guggenheim upgrades Autodesk, raises price target</a></h4><ul><li>        Guggenheim upgrades Autodesk (NASDAQ:<a href='https://seekingalpha.com/symbol/ADSK' title='Autodesk, Inc.'>ADSK</a>) from Neutral to Buy and raises the price target by $40 to $150.</li><li>               Analyst Nate Cunningham says a survey he conducted of 250 Autodesk customers showed that he was wrong in thinking customers wouldn&rsquo;t tolerate the raised product prices.&nbsp;</li><li>                  Autodesk has moved from software license sales to a subscription model, a successful transition that Cunningham thinks led to the &ldquo;early innings of a compelling multi-year secular opportunity.&rdquo;    </li><li>               Source: <a href=\"http://www.barrons.com/articles/autodesk-rising-customers-just-fine-with-higher-prices-says-guggenheim-1510591049\" target=\"_blank\">Barron&rsquo;s</a>.&nbsp;&nbsp;&nbsp;</li><li>Autodesk shares are&nbsp;<font color='green'>up 0.87%</font>&nbsp;to $124.18.</li></ul><div class=\"tiny-share-widget\" data-id=\"3311540\" data-linked=\"Guggenheim upgrades Autodesk, raises price target\" data-tweet=\"$ADSK - Guggenheim upgrades Autodesk, raises price target https://seekingalpha.com/news/3311540-guggenheim-upgrades-autodesk-raises-price-target?source=tweet\" data-url=\"https://seekingalpha.com/news/3311540-guggenheim-upgrades-autodesk-raises-price-target\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:02 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3311538\" data-ts=\"1510595948\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3311538-financials-top-5-gainers-losers-of-1-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Financials - Top 5 Gainers / Losers as of 1:00 PM</a></h4><ul><li><b>Gainers:</b> GGP <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/SGLB' title='Sigma Labs, Inc.'>SGLB</a> <font color='green'>+5%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/RTNB' title='root9B Technologies, Inc.'>OTC:RTNB</a> <font color='red'>-50%</font>. <a href='https://seekingalpha.com/symbol/AFSI' title='AmTrust Financial Services, Inc.'>AFSI</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/PN' title='Patriot National, Inc.'>PN</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/SCM' title='Stellus Capital Investment Corporation'>SCM</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/WETF' title='WisdomTree Investments, Inc.'>WETF</a> <font color='red'>-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3311538\" data-linked=\"Financials - Top 5 Gainers / Losers as of 1:00 PM\" data-tweet=\"$BPR $SGLB $RTNB - Financials - Top 5 Gainers / Losers as of 1:00 PM https://seekingalpha.com/news/3311538-financials-top-5-gainers-losers-of-1-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3311538-financials-top-5-gainers-losers-of-1-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:59 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3311536\" data-ts=\"1510595929\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ET\" target=\"_blank\">ET</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3311536-go-long-energy-transfer-partners-short-ete-hedgeye-says\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Go long Energy Transfer Partners but short ETE, Hedgeye says</a></h4><ul>     <li>Hedgeye analyst Kevin Kaiser said in a note today to go long Energy Transfer Partners (ETP <font color='green'>+1.8%</font>) while shorting Energy Transfer Equity (ETP <font color='green'>+1.8%</font>); both companies are trading higher today.</li>     <li>\"ETP unitholders have long suffered egregious corporate governance and value destruction at the hands of its GP, owned by ETE,\" according to Kaiser, who proposes an \"unprecedented, though much warranted, transaction of removing a GP from a MLP.\"</li>     <li>Kaiser sees ETP is headed to $30-$40/unit, or 80%-140% upside, but ETE tumbling to $3-$7/unit, or 60%-80% downside.</li>     <li>Source:&nbsp;Bloomberg First Word</li> </ul><div class=\"tiny-share-widget\" data-id=\"3311536\" data-linked=\"Go long Energy Transfer Partners but short ETE, Hedgeye says\" data-tweet=\"$ET - Go long Energy Transfer Partners but short ETE, Hedgeye says https://seekingalpha.com/news/3311536-go-long-energy-transfer-partners-short-ete-hedgeye-says?source=tweet\" data-url=\"https://seekingalpha.com/news/3311536-go-long-energy-transfer-partners-short-ete-hedgeye-says\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:58 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>282&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3311534\" data-ts=\"1510595438\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CBL\" target=\"_blank\">CBL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3311534-dont-expect-m-to-bail-out-b-malls-jefferies\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Don&#39;t expect M&amp;A to bail out &#39;B&#39; malls - Jefferies</a></h4><ul><li>Based on Brookfield's <a href=\"https://seekingalpha.com/news/3311530-sell-side-sees-sale-price-ggp-going-higher\" target=\"_blank\">buyout offer for</a> GGP, and a sizable stake in Macerich <a href=\"https://seekingalpha.com/news/3311231-another-nice-session-malls-dan-loebs-macerich-stake\" target=\"_blank\">taken by Dan Loeb</a>, the rough patch for mall operators has stirred M&amp;A/activist animal spirits.</li><li>Operators of \"B\" malls, however, shouldn't take too much comfort, says analyst&nbsp;Omotayo Okusanya, as this sort of activity may be limited to \"A\" players.</li><li>Sharply lower today: CBL &amp; Associates (<a href='https://seekingalpha.com/symbol/CBL' title='CBL & Associates Properties, Inc.'>CBL</a> <font color='red'>-5.5%</font>), PREIT (<a href='https://seekingalpha.com/symbol/PEI' title='Pennsylvania Real Estate Investment Trust'>PEI</a> <font color='red'>-2.5%</font>), Washington Prime (<a href='https://seekingalpha.com/symbol/WPG' title='Washington Prime Group, Inc.'>WPG</a> <font color='red'>-2%</font>)</li></ul><div class=\"tiny-share-widget\" data-id=\"3311534\" data-linked=\"Don&#39;t expect M&amp;A to bail out &#39;B&#39; malls - Jefferies\" data-tweet=\"$CBL $CBL $PEI - Don&#39;t expect M&amp;A to bail out &#39;B&#39; malls - Jefferies https://seekingalpha.com/news/3311534-dont-expect-m-to-bail-out-b-malls-jefferies?source=tweet\" data-url=\"https://seekingalpha.com/news/3311534-dont-expect-m-to-bail-out-b-malls-jefferies\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:50 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>45&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3311531\" data-ts=\"1510595142\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3311531-midday-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers / Losers</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/ZX' title='China Zenix Auto International'>ZX</a> <font color='green'>+35%</font>. <a href='https://seekingalpha.com/symbol/ROKU' title='Roku Inc.'>ROKU</a> <font color='green'>+35%</font>. <a href='https://seekingalpha.com/symbol/CHKE' title='Cherokee Inc.'>CHKE</a> <font color='green'>+32%</font>. <a href='https://seekingalpha.com/symbol/NVFY' title='Nova Lifestyle, Inc.'>NVFY</a> <font color='green'>+28%</font>. <a href='https://seekingalpha.com/symbol/EKSO' title='Ekso Bionics Holdings, Inc.'>EKSO</a> <font color='green'>+25%</font>. <a href='https://seekingalpha.com/symbol/MAT' title='Mattel, Inc.'>MAT</a> <font color='green'>+21%</font>. <a href='https://seekingalpha.com/symbol/GTXI' title='GTx, Inc.'>GTXI</a> <font color='green'>+21%</font>. <a href='https://seekingalpha.com/symbol/ONCS' title='OncoSec Medical Incorporated'>ONCS</a> <font color='green'>+21%</font>. <a href='https://seekingalpha.com/symbol/EVK' title='Ever-Glory International Group, Inc'>EVK</a> <font color='green'>+19%</font>. <a href='https://seekingalpha.com/symbol/ZYME' title='Zymeworks'>ZYME</a> <font color='green'>+18%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/RTNB' title='root9B Technologies, Inc.'>OTC:RTNB</a> <font color='red'>-52%</font>. <a href='https://seekingalpha.com/symbol/CALA' title='Calithera Biosciences'>CALA</a> <font color='red'>-24%</font>. <a href='https://seekingalpha.com/symbol/CRIS' title='Curis, Inc.'>CRIS</a> <font color='red'>-19%</font>. <a href='https://seekingalpha.com/symbol/INFI' title='Infinity Pharmaceuticals, Inc.'>INFI</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/QTM-OLD' title='Quantum Corporation'>QTM-OLD</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/KEG' title='Key Energy Services, Inc.'>KEG</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/IMMU' title='Immunomedics, Inc.'>IMMU</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/ECYT' title='Endocyte, Inc.'>ECYT</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/CTXR' title='Citius Pharmaceuticals Inc.'>CTXR</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/DCIX' title='Diana Containerships Inc.'>DCIX</a> <font color='red'>-10%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3311531\" data-linked=\"Midday Gainers / Losers\" data-tweet=\"$ZXAIY $ROKU $APEX - Midday Gainers / Losers https://seekingalpha.com/news/3311531-midday-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3311531-midday-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:45 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3311530\" data-ts=\"1510594672\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BPR\" target=\"_blank\">BPR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3311530-sell-side-sees-sale-price-for-ggp-going-higher\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sell-side sees sale price for GGP going higher</a></h4><ul><li>One of the Street's bigger bulls on GGP, Boenning &amp; Scattergood's Floris van Dijkum figures the company is worth $35 per share, and expects at least $30 will be necessary to seal a purchase.</li><li>Brookfield's (<a href='https://seekingalpha.com/symbol/BAM' title='Brookfield Asset Management Inc.'>BAM</a>, <a href='https://seekingalpha.com/symbol/BPY' title='Brookfield Property Partners L.P.'>BPY</a>) past M&amp;A behavior suggests they will eventually up their bid to $25-$26 from the current $23, says Wells Fargo's Jeffrey Donnelly.</li><li>Meanwhile, Sandler O'Neill says it's going to take more than $28 per share.</li><li>Source: Bloomberg</li><li>Shares&nbsp;<font color='green'>up 7.4%</font>&nbsp;to $23.84.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3311469-mall-names-mostly-higher-brookfield-bid-ggp-made-official\" target=\"_blank\">Mall names mostly higher after Brookfield bid for GGP made official</a> (Nov. 13)</li></ul><div class=\"tiny-share-widget\" data-id=\"3311530\" data-linked=\"Sell-side sees sale price for GGP going higher\" data-tweet=\"$BPR $BPR $BAM - Sell-side sees sale price for GGP going higher https://seekingalpha.com/news/3311530-sell-side-sees-sale-price-for-ggp-going-higher?source=tweet\" data-url=\"https://seekingalpha.com/news/3311530-sell-side-sees-sale-price-for-ggp-going-higher\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:37 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3311529\" data-ts=\"1510594565\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GALT\" target=\"_blank\">GALT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3311529-galectins-gr-mdminus-02-mercks-keytruda-shows-positive-effect-in-melanoma-patients-in-early\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Galectin&#39;s GR-MD-02 + Merck&#39;s Keytruda shows positive effect in melanoma patients in early-stage study; shares up 7%</a></h4><ul><li><a href=\"https://seekingalpha.com/pr/16999807-combination-immunotherapy-pembrolizumab-galectinminus-3-inhibitor-gr-mdminus-02-shows\" target=\"_blank\">Preliminary data</a> from a Phase 1b clinical trial assessing the combination of Galectin Therapeutics' (<a href='https://seekingalpha.com/symbol/GALT' title='Galectin Therapeutics, Inc.'>GALT</a> <font color='green'>+6.6%</font>) GR-MD-02 and Merck's (<a href='https://seekingalpha.com/symbol/MRK' title='Merck & Co Inc.'>MRK</a> <font color='red'>-0.4%</font>) KEYTRUDA (pembrolizumab) in patients with solid tumors, including advanced melanoma, showed a treatment effect. The results were presented at the SITC Annual Meeting in National Harbor, MD.</li><li>In melanoma, patients receiving five courses of the three-week combo therapy&nbsp;experienced a 63% response rate (n=5/8), including two complete responders. The response rate for pembrolizumab alone in this population is ~33%.</li><li>All patients in the second cohort (higher dose of 4 mg/kg of GR-MD-02) responded (n=3/3).</li><li>Enrollment in the third cohort (8 mg/kg of GR-MD-02) is underway.</li><li>Additional data should be available in mid-2018 when the company decides on advancing into Phase 2.</li><li><a href=\"http://galectintherapeutics.com/what-we-do/develop-proprietary-compounds-for-disease/development-program/\" target=\"_blank\">GR-MD-02</a>&nbsp;is a complex carbohydrate drug that targets&nbsp;<a href=\"https://en.wikipedia.org/wiki/Galectin-3\" target=\"_blank\">galectin-3</a>, a protein that plays a key role in the development of fatty liver disease and fibrosis.</li></ul><div class=\"tiny-share-widget\" data-id=\"3311529\" data-linked=\"Galectin&#39;s GR-MD-02 + Merck&#39;s Keytruda shows positive effect in melanoma patients in early-stage study; shares up 7%\" data-tweet=\"$GALT $GALT $MRK - Galectin&#39;s GR-MD-02 + Merck&#39;s Keytruda shows positive effect in melanoma patients in early-stage study; shares up 7% https://seekingalpha.com/news/3311529-galectins-gr-mdminus-02-mercks-keytruda-shows-positive-effect-in-melanoma-patients-in-early?source=tweet\" data-url=\"https://seekingalpha.com/news/3311529-galectins-gr-mdminus-02-mercks-keytruda-shows-positive-effect-in-melanoma-patients-in-early\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:36 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3311527\" data-ts=\"1510593918\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PVG\" target=\"_blank\">PVG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3311527-pretium-resourcesminus-8-after-q3-earnings-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pretium Resources -8% after Q3 earnings results</a></h4><ul>     <li>Pretium Resources (<a href='https://seekingalpha.com/symbol/PVG' title='Pretium Resources Inc'>PVG</a> <font color='red'>-8.1%</font>) plunges after releasing <a href=\"https://seekingalpha.com/news/3311281-pretium-resources-reports-q3-results\" target=\"_blank\">Q3 earnings</a> and revenues that came in below limited analyst coverage, giving back all of the gains amassed since reporting strong production at its flagship Brucejack mine <a href=\"https://seekingalpha.com/news/3300472-pretium-resources-plus-22-percent-strong-brucejack-mine-production\" target=\"_blank\">a month ago</a>.</li>     <li>PVG says Brucejack produced 82.2K oz. of gold and 83.233 oz. of silver during Q3 but sold only 55.4K oz. of gold and 19.8K oz. of silver.</li>     <li>Total cash cost was $656/oz. of gold sold and all-in sustained cost was $788/oz. of gold sold; PVG says total cash costs and AISC should decrease as gold sales catch up with production.</li></ul><div class=\"tiny-share-widget\" data-id=\"3311527\" data-linked=\"Pretium Resources -8% after Q3 earnings results\" data-tweet=\"$PVG - Pretium Resources -8% after Q3 earnings results https://seekingalpha.com/news/3311527-pretium-resourcesminus-8-after-q3-earnings-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3311527-pretium-resourcesminus-8-after-q3-earnings-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:25 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>46&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3311526\" data-ts=\"1510593709\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/QTS\" target=\"_blank\">QTS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3311526-qtsplus-1_5-on-co-location-deal-amazon-web-services\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">QTS +1.5% on co-location deal with Amazon Web Services</a></h4><ul>   <li>QTS Realty Trust (NYSE:<a href='https://seekingalpha.com/symbol/QTS' title='QTS Realty Trust, Inc.'>QTS</a>) shares have jumped at midday, <font color='green'>up 1.5%</font>, after word of a <a href=\"https://seekingalpha.com/pr/17000325-qts-enters-strategic-collaboration-amazon-web-services-deliver-colocation-cloud-customers\" target=\"_blank\">strategic tie-up with Amazon.com</a> on direct-connected co-location for customers of Amazon Web Services.</li>    <li>The deal involves QTS CloudRamp, a preconfigured turnkey solution targeting customers who need short-term AWS co-location for cloud migration, or longer-term hybrid workflows.</li>    <li>For those with bigger requirements, QTS and AWS promise tailored hybrid IT solutions built on the co-location infrastructure.</li>    <li>The CloudRamp service is now available via AWS Direct at QTS data centers in Chicago; Piscataway, N.J.; Richmond, Va.; and Santa Clara, Calif. And the tailored hybrid IT solutions are available across the 21 QTS data centers.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3311526\" data-linked=\"QTS +1.5% on co-location deal with Amazon Web Services\" data-tweet=\"$QTS - QTS +1.5% on co-location deal with Amazon Web Services https://seekingalpha.com/news/3311526-qtsplus-1_5-on-co-location-deal-amazon-web-services?source=tweet\" data-url=\"https://seekingalpha.com/news/3311526-qtsplus-1_5-on-co-location-deal-amazon-web-services\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:21 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3311525\" data-ts=\"1510593386\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TDC\" target=\"_blank\">TDC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3311525-summit-redstone-upgrades-teradata\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Summit Redstone upgrades Teradata</a></h4><ul><li>        Summit Redstone <a href=\"http://www.briefing.com/DisplayArticle/ArticlePopup.aspx?ArticleId=IN20171113065638TDC\" target=\"_blank\">upgrades</a> Teradata (NYSE:<a href='https://seekingalpha.com/symbol/TDC' title='Teradata Corporation'>TDC</a>) from Hold to Buy &nbsp;</li><li>        Latest analyst recommendations for Teradata (via <a href=\"https://markets.ft.com/data/equities/tearsheet/forecasts?s=TDC:NYQ\" target=\"_blank\">FT</a>): 1 Buy, 1 Outperform, 12 Hold, 6 Underperform, and 2 Sell.</li><li>               Median price target: $31.50.&nbsp;</li><li>               Teradata shares are&nbsp;<font color='green'>up 1.9%</font>&nbsp;to $36.02.&nbsp; &nbsp;&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3311525\" data-linked=\"Summit Redstone upgrades Teradata\" data-tweet=\"$TDC - Summit Redstone upgrades Teradata https://seekingalpha.com/news/3311525-summit-redstone-upgrades-teradata?source=tweet\" data-url=\"https://seekingalpha.com/news/3311525-summit-redstone-upgrades-teradata\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:16 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3311524\" data-ts=\"1510592627\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TURN\" target=\"_blank\">TURN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3311524-thestreet-up-32-after-180-degree-capital-investment\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">TheStreet up 32% after 180 Degree Capital investment</a></h4><ul><li>180 Degree Capital (<a href='https://seekingalpha.com/symbol/TURN' title='180 Degree Capital Corp'>TURN</a> <font color='green'>+0.5%</font>) announces it's led a $7.85M funding round for TheStreet (<a href='https://seekingalpha.com/symbol/TST' title='TheStreet, Inc.'>TST</a> <font color='green'>+32%</font>).</li><li>Proceeds were used to retire TheStreet's preferred stock.</li><li>Alongside, 180 Degree Chairman and CEO Kevin Rendino has joined TheStreet's board.</li><li>180 Degree is <a href=\"http://join.freeconferencecall.com/daniel8166\" target=\"_blank\">planning a conference call </a>today at 4 ET.</li><li>Source: <a href=\"https://seekingalpha.com/pr/16999770-b-180-b-b-degree-b-capital-corp-leads-investment-thestreet-inc-investment-enables-removal\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3311524\" data-linked=\"TheStreet up 32% after 180 Degree Capital investment\" data-tweet=\"$TURN $TURN $TST - TheStreet up 32% after 180 Degree Capital investment https://seekingalpha.com/news/3311524-thestreet-up-32-after-180-degree-capital-investment?source=tweet\" data-url=\"https://seekingalpha.com/news/3311524-thestreet-up-32-after-180-degree-capital-investment\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:03 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3311523\" data-ts=\"1510592516\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3311523-consumer-top-gainers-losers-of-12-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Consumer - Top Gainers / Losers as of 12:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/NVFY' title='Nova Lifestyle, Inc.'>NVFY</a> <font color='green'>+31%</font>. <a href='https://seekingalpha.com/symbol/ZX' title='China Zenix Auto International'>ZX</a> <font color='green'>+31%</font>. <a href='https://seekingalpha.com/symbol/MAT' title='Mattel, Inc.'>MAT</a> <font color='green'>+21%</font>. <a href='https://seekingalpha.com/symbol/EVK' title='Ever-Glory International Group, Inc'>EVK</a> <font color='green'>+16%</font>. <a href='https://seekingalpha.com/symbol/SQBG' title='Sequential Brands Group, Inc.'>SQBG</a> <font color='green'>+12%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/KBSF' title='KBS Fashion Group Limited'>KBSF</a> <font color='red'>-7%</font>. LTEA <font color='red'>-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3311523\" data-linked=\"Consumer - Top Gainers / Losers as of 12:00 pm\" data-tweet=\"$NVFY $ZXAIY $MAT - Consumer - Top Gainers / Losers as of 12:00 pm https://seekingalpha.com/news/3311523-consumer-top-gainers-losers-of-12-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3311523-consumer-top-gainers-losers-of-12-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:01 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3311520\" data-ts=\"1510592112\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AU\" target=\"_blank\">AU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3311520-anglogoldplus-1_5-rbc-upgrades-to-outperform\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AngloGold +1.5% as RBC upgrades to Outperform</a></h4><ul>     <li>AngloGold Ashanti (<a href='https://seekingalpha.com/symbol/AU' title='AngloGold Ashanti Limited'>AU</a> <font color='green'>+1.5%</font>) is higher after&nbsp;RBC Capital <a href=\"https://www.streetinsider.com/Upgrades/RBC+Capital+Upgrades+AngloGold+Ashanti+%28AU%29+to+Outperform/13494439.html\" target=\"_blank\">upgrades</a> shares to Outperform from Sector Perform with an $11.50 price target, as the firm believes the sale of high-cost South African assets will kick-start a re-rating in the stock, which has turned in a lackluster YTD performance.</li><li>RBC also thinks international investors would prefer to see a strategy shift towards higher-margin mines such as those seen in AU's international division, and thus sees the sale of higher-cost South African assets as a welcome move.</li><li>Along with other catalysts - Obuasi update, Long Island study approval, ramp-up of Kibali, free cash flow increase - the sale should help reduce AU's NAV discount vs. South African and international peers, RBC says.</li></ul><div class=\"tiny-share-widget\" data-id=\"3311520\" data-linked=\"AngloGold +1.5% as RBC upgrades to Outperform\" data-tweet=\"$AU - AngloGold +1.5% as RBC upgrades to Outperform https://seekingalpha.com/news/3311520-anglogoldplus-1_5-rbc-upgrades-to-outperform?source=tweet\" data-url=\"https://seekingalpha.com/news/3311520-anglogoldplus-1_5-rbc-upgrades-to-outperform\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:55 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3311516\" data-ts=\"1510591576\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DMRC\" target=\"_blank\">DMRC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3311516-digimarc-announces-12m-registered-direct-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Digimarc announces $12M registered direct offering</a></h4><ul><li>        Digimarc (NASDAQ:<a href='https://seekingalpha.com/symbol/DMRC' title='Digimarc Corporation'>DMRC</a>) <a href=\"https://seekingalpha.com/pr/17000194-digimarc-announces-registered-direct-offering-common-stock\" target=\"_blank\">announces</a> a registered direct offering for 331,034 common shares at $36.25 per share.</li><li>               The $12M offering doesn&rsquo;t have an underwriter and the company will use the proceeds for general corporate purposes.&nbsp;</li><li>               Digimarc hopes to close the offer soon since the close date is &ldquo;on or about November 13.&rdquo;&nbsp;</li><li>               Digimarc shares are&nbsp;<font color='green'>up 3.66%</font>. &nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3311516\" data-linked=\"Digimarc announces $12M registered direct offering\" data-tweet=\"$DMRC - Digimarc announces $12M registered direct offering https://seekingalpha.com/news/3311516-digimarc-announces-12m-registered-direct-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3311516-digimarc-announces-12m-registered-direct-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:46 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3311515\" data-ts=\"1510590991\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KBR\" target=\"_blank\">KBR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3311515-kbrminus-10-on-worries-over-u-k-defense-spending\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">KBR -10% on worries over U.K. defense spending</a></h4><ul>     <li>Today's selloff in KBR (<a href='https://seekingalpha.com/symbol/KBR' title='KBR, Inc.'>KBR</a> <font color='red'>-10.2%</font>) shares is at least partially attributed to a poor performance at Ultra Electronics (<a href='https://seekingalpha.com/symbol/UEHPF' title='Ultra Electronics Holdings Plc.'>OTC:UEHPF</a>, <a href='https://seekingalpha.com/symbol/UEHPY' title='Ultra Electronics Holdings Plc. ADR'>OTCPK:UEHPY</a>), according to Briefing.com.</li>     <li>In particular, Ultra said today that the U.K. defense market had become <a href=\"http://www.telegraph.co.uk/business/2017/11/13/ultra-electronics-shares-plunge-warns-profits-axes-chief-executive/\" target=\"_blank\">increasingly difficult</a> in H2 due to budget pressures in defense programs, along with the departure of CEO Rakesh Sharma; last Friday, Ultra said a decision on its purchase of U.S. firm Sparton (NYSE:<a href='https://seekingalpha.com/symbol/SPA' title='Sparton Corporation'>SPA</a>) would be delayed until March.</li>     <li>In its <a href=\"https://seekingalpha.com/news/3305927-kbr-beats-0_02-misses-revenue\" target=\"_blank\">Q3 earnings</a> report, KBR said the U.K. would remain a key driver and growth engine for the company.</li></ul><div class=\"tiny-share-widget\" data-id=\"3311515\" data-linked=\"KBR -10% on worries over U.K. defense spending\" data-tweet=\"$KBR $KBR $UEHPF - KBR -10% on worries over U.K. defense spending https://seekingalpha.com/news/3311515-kbrminus-10-on-worries-over-u-k-defense-spending?source=tweet\" data-url=\"https://seekingalpha.com/news/3311515-kbrminus-10-on-worries-over-u-k-defense-spending\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:36 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3311511\" data-ts=\"1510590475\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/QCOM\" target=\"_blank\">QCOM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3311511-broadcom-after-rejection-fully-committed-to-qualcomm-buyout\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Broadcom after rejection: &#39;Fully committed&#39; to Qualcomm buyout</a></h4><ul>   <li>After getting an on-the-record rejection of its buyout bid for Qualcomm (NASDAQ:<a href='https://seekingalpha.com/symbol/QCOM' title='Qualcomm Inc.'>QCOM</a>), Broadcom (NASDAQ:<a href='https://seekingalpha.com/symbol/AVGO' title='Broadcom Limited'>AVGO</a>) says it's <a href=\"https://seekingalpha.com/pr/17000223-broadcom-remains-fully-committed-acquisition-qualcomm\" target=\"_blank\">still \"fully committed\"</a> to the deal.</li>    <li>Broadcom shares are now <font color='green'>up 0.3%</font> on the day; Qualcomm is <font color='green'>up 1.8%</font>, at session highs.</li>    <li>\"This transaction will create a strong, global company with an impressive portfolio of industry-leading technologies and products, and we have received positive feedback from key customers about this combination,\" says Broadcom chief Hock Tan. \"We continue to believe our proposal represents the most attractive, value-enhancing alternative available to Qualcomm stockholders and we are encouraged by their reaction.</li>    <li>\"Many have expressed to us their desire that Qualcomm meet with us to discuss our proposal. It remains our strong preference to engage cooperatively with Qualcomm's Board of Directors and management team.\"</li>    <li>Broadcom says its proposal stands regardless of the outcome of Qualcomm's pending acquisition of NXP Semiconductors (NASDAQ:<a href='https://seekingalpha.com/symbol/NXPI' title='NXP Semiconductors'>NXPI</a>).</li><li>Previously: <a href=\"https://seekingalpha.com/news/3311444-qualcomm-rejects-takeover-bid-broadcom-value-regulatory-concern\" target=\"_blank\">Qualcomm rejects takeover bid from Broadcom on value, regulatory concern</a> (Nov. 13 2017)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3311511\" data-linked=\"Broadcom after rejection: &#39;Fully committed&#39; to Qualcomm buyout\" data-tweet=\"$QCOM $QCOM $AVGO - Broadcom after rejection: &#39;Fully committed&#39; to Qualcomm buyout https://seekingalpha.com/news/3311511-broadcom-after-rejection-fully-committed-to-qualcomm-buyout?source=tweet\" data-url=\"https://seekingalpha.com/news/3311511-broadcom-after-rejection-fully-committed-to-qualcomm-buyout\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:27 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>57&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3311509\" data-ts=\"1510590151\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/UHS\" target=\"_blank\">UHS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3311509-uhs-continues-selloff-shares-down-2-on-video-of-staff-member-assaulting-patient\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">UHS continues selloff; shares down 2% on video of staff member assaulting patient</a></h4><ul><li>Universal Health Services (<a href='https://seekingalpha.com/symbol/UHS' title='Universal Health Services Inc.'>UHS</a> <font color='red'>-1.7%</font>) is in the red again. Share have sold off almost&nbsp;<font color='red'>16%</font>&nbsp;since October 23 when it reported Q3 results (10/25) that missed consensus.</li><li>A <a href=\"https://www.buzzfeed.com/rosalindadams/videos-show-uhs-hospital-staff-assaulting-young-patients?utm_term=.ww8qd4zW3#.tcyP90Nl2\" target=\"_blank\">video </a>is going viral this morning showing what appears to be an assault by a staff member on a patient with a cast on his right leg.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3304082-universal-health-services-misses-0_19-misses-revenue\" target=\"_blank\">Universal Health Services misses by $0.19, misses on revenue</a> (Oct. 25)</li></ul><div class=\"tiny-share-widget\" data-id=\"3311509\" data-linked=\"UHS continues selloff; shares down 2% on video of staff member assaulting patient\" data-tweet=\"$UHS - UHS continues selloff; shares down 2% on video of staff member assaulting patient https://seekingalpha.com/news/3311509-uhs-continues-selloff-shares-down-2-on-video-of-staff-member-assaulting-patient?source=tweet\" data-url=\"https://seekingalpha.com/news/3311509-uhs-continues-selloff-shares-down-2-on-video-of-staff-member-assaulting-patient\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:22 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3311504\" data-ts=\"1510589632\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BSPM\" target=\"_blank\">BSPM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3311504-biostar-up-30-on-apparent-chatroom-activity\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Biostar up 30% on apparent chatroom activity</a></h4><ul><li>Thinly traded nano cap Biostar Pharmaceuticals (<a href='https://seekingalpha.com/symbol/BSPM' title='Biostar Pharmaceutic'>OTC:BSPM</a> <font color='green'>+29.4%</font>) jumps on almost an 8x surge in volume in response to supposed&nbsp;<a href=\"https://investorshub.advfn.com/Biostar-Pharmaceuticals-Inc-BSPM-16055/\" target=\"_blank\">chatroom </a>activity.</li><li>The company is facing <a href=\"https://seekingalpha.com/pr/16925265-biostar-announces-receipt-nasdaq-continued-listing-deficiency-notice\" target=\"_blank\">delisting </a>from Nasdaq due to its failure to file its 10-Q for the quarter ended June 30.</li><li>Investors should exercise caution here.</li></ul><div class=\"tiny-share-widget\" data-id=\"3311504\" data-linked=\"Biostar up 30% on apparent chatroom activity\" data-tweet=\"$BSPM - Biostar up 30% on apparent chatroom activity https://seekingalpha.com/news/3311504-biostar-up-30-on-apparent-chatroom-activity?source=tweet\" data-url=\"https://seekingalpha.com/news/3311504-biostar-up-30-on-apparent-chatroom-activity\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:13 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3311505\" data-ts=\"1510589426\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ECIFF\" target=\"_blank\">ECIFF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3311505-edf-sharesminus-10-after-reduced-ebitda-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">EDF shares -10% after reduced EBITDA guidance</a></h4><ul>     <li>Electricite de France (<a href='https://seekingalpha.com/symbol/ECIFF' title='Electricite de France SA'>OTCPK:ECIFF</a>, <a href='https://seekingalpha.com/symbol/ECIFY' title='Electricite de France SA ADR'>OTCPK:ECIFY</a>) tumbles 10% in European trading after the utility company <a href=\"https://www.marketwatch.com/story/edf-shares-tumble-after-company-cuts-guidance-2017-11-13\" target=\"_blank\">cuts its 2018 financial targets</a> as it faces \"unfavorable developments\" in France and the U.K.</li>     <li>EDF says it still expects a \"significant rebound\" in EBITDA at &euro;14.6B-&euro;15.3B, but its previous target was for at least &euro;15.2B.</li>     <li>The company cites several headwinds, including \"the expected erosion of electricity consumption in France,\" the \"lower availability of some nuclear reactors at the beginning of 2018\" and \"the drop in the capacity compensation\" in the U.K.</li></ul><div class=\"tiny-share-widget\" data-id=\"3311505\" data-linked=\"EDF shares -10% after reduced EBITDA guidance\" data-tweet=\"$ECIFF $ECIFF $ECIFY - EDF shares -10% after reduced EBITDA guidance https://seekingalpha.com/news/3311505-edf-sharesminus-10-after-reduced-ebitda-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3311505-edf-sharesminus-10-after-reduced-ebitda-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:10 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3311500\" data-ts=\"1510588809\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3311500-healthcare-top-5-gainers-losers-of-11-00\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare - Top 5 Gainers / Losers as of 11:00</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/BSPM' title='Biostar Pharmaceutic'>OTC:BSPM</a> <font color='green'>+27%</font>. <a href='https://seekingalpha.com/symbol/EKSO' title='Ekso Bionics Holdings, Inc.'>EKSO</a> <font color='green'>+27%</font>.<a href='https://seekingalpha.com/symbol/ZYME' title='Zymeworks'>ZYME</a> <font color='green'>+26%</font>. <a href='https://seekingalpha.com/symbol/NKTR' title='Nektar Therapeutics'>NKTR</a> <font color='green'>+17%</font>. <a href='https://seekingalpha.com/symbol/ONCS' title='OncoSec Medical Incorporated'>ONCS</a> <font color='green'>+17%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/CALA' title='Calithera Biosciences'>CALA</a> <font color='red'>-15%</font>. <a href='https://seekingalpha.com/symbol/FONR' title='Fonar Corporation'>FONR</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/AMDA' title='Amedica Corporation'>AMDA</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/INFI' title='Infinity Pharmaceuticals, Inc.'>INFI</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/SGYP' title='Synergy Pharmaceuticals, Inc.'>SGYP</a> <font color='red'>-9%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3311500\" data-linked=\"Healthcare - Top 5 Gainers / Losers as of 11:00\" data-tweet=\"$BSPM $EKSO $ZYME - Healthcare - Top 5 Gainers / Losers as of 11:00 https://seekingalpha.com/news/3311500-healthcare-top-5-gainers-losers-of-11-00?source=tweet\" data-url=\"https://seekingalpha.com/news/3311500-healthcare-top-5-gainers-losers-of-11-00\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:00 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3311499\" data-ts=\"1510588778\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CALA\" target=\"_blank\">CALA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3311499-nektars-gain-calitheras-pain-on-opdivo-combo-treatments-shares-down-15\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nektar&#39;s gain Calithera&#39;s pain on Opdivo combo treatments; shares down 15%</a></h4><ul><li>Calithera Biosciences (<a href='https://seekingalpha.com/symbol/CALA' title='Calithera Biosciences'>CALA</a> <font color='red'>-14.9%</font>) is under pressure on modestly higher volume in response to Nektar Therapeutics' (<a href='https://seekingalpha.com/symbol/NKTR' title='Nektar Therapeutics'>NKTR</a> <font color='green'>+16.6%</font>) <a href=\"https://seekingalpha.com/pr/16999261-first-data-nktrminus-214-combination-opdivo-nivolumab-patients-stage-iv-melanoma-renal-cell\" target=\"_blank\">announcement</a> of preliminary data on the combination of NKTR-214 and Bristol-Myers Squibb's (<a href='https://seekingalpha.com/symbol/BMY' title='Bristol-Myers Squibb Company'>BMY</a> <font color='red'>-0.3%</font>) Opdivo (nivolumab) in solid tumors. The results, albeit on a small number of patients, appear to trump Calithera's CB-839/Opdivo combo.</li><li>In melanoma, the response rate favored NKTR-214 63% (n=7/11) to 19% (n=3/16) for CB-839.</li><li>In non-small cell lung cancer, NKTR-214 produced a 75% (n=3/4) response rate, including one complete responder in patients who progressed on prior chemo compared to a 67% (n=4/6) disease control rate &#40;DCR&#41;&nbsp;for CB-839 (all stable disease, no responders) in patients who were progressing on checkpoint inhibitor therapy.</li><li>In kidney cancer, NKTR-214 showed a 46% response rate and DCR of 85% (treatment-naive) compared to a 21% (n=4/19) response rate and 74% DCR for CB-839.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3311468-combination-opdivo-nektars-nktrminus-214-show-positive-effect-advanced-lung-cancer-phase-1-2\" target=\"_blank\">Combination of Opdivo and Nektar's NKTR-214 show positive effect in advanced lung cancer in Phase 1/2 study</a> (Nov. 13)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3309179-mid-stage-study-shows-positive-effect-calitheras-cbminus-839-bristol-myers-opdivo\" target=\"_blank\">Mid-stage study shows positive effect of Calithera's CB-839 + Bristol-Myers' Opdivo</a> (Nov. 7)</li></ul><div class=\"tiny-share-widget\" data-id=\"3311499\" data-linked=\"Nektar&#39;s gain Calithera&#39;s pain on Opdivo combo treatments; shares down 15%\" data-tweet=\"$CALA $CALA $NKTR - Nektar&#39;s gain Calithera&#39;s pain on Opdivo combo treatments; shares down 15% https://seekingalpha.com/news/3311499-nektars-gain-calitheras-pain-on-opdivo-combo-treatments-shares-down-15?source=tweet\" data-url=\"https://seekingalpha.com/news/3311499-nektars-gain-calitheras-pain-on-opdivo-combo-treatments-shares-down-15\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:59 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>48&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3311497\" data-ts=\"1510588458\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BAA\" target=\"_blank\">BAA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3311497-banrominus-44-on-going-concern-doubts\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Banro -44% on going concern doubts</a></h4><ul>     <li>Banro (<a href='https://seekingalpha.com/symbol/BAA' title='Banro Corporation'>BAA</a> <font color='red'>-44.1%</font>) plunges after warning that it is <a href=\"https://seekingalpha.com/pr/16999481-banro-provides-corporate-update\" target=\"_blank\">running out of cash</a> and funding options to service its  debt, and provide working capital for operations in the Democratic Republic of Congo.</li>     <li>Also, mining operations at BAA's Namoya mine in the Democratic Republic of the Congo remain suspended due to the ongoing closure of road access to the mine site.</li>     <li>A special committee established by the company's board says \"there is no reasonable prospect that a successful capital raise (whether debt, equity or a combination) could be completed at the current time at a level sufficient to refinance the company's existing indebtedness and to address its working capital requirements.\"</li> </ul><div class=\"tiny-share-widget\" data-id=\"3311497\" data-linked=\"Banro -44% on going concern doubts\" data-tweet=\"$BAA - Banro -44% on going concern doubts https://seekingalpha.com/news/3311497-banrominus-44-on-going-concern-doubts?source=tweet\" data-url=\"https://seekingalpha.com/news/3311497-banrominus-44-on-going-concern-doubts\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:54 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3311496\" data-ts=\"1510588250\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JD\" target=\"_blank\">JD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3311496-jd-complus-4_7-after-unexpected-swing-to-profit-on-heavy-sales\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">JD.com +4.7% after unexpected swing to profit on heavy sales</a></h4><ul>    <li>JD.com (NASDAQ:<a href='https://seekingalpha.com/symbol/JD' title='JD.com'>JD</a>) is <font color='green'>up 4.7%</font> in U.S. trade after its <a href=\"https://seekingalpha.com/news/3311324-jd-com-beats-0_13-beats-revenue\" target=\"_blank\">Q3 profits</a> topped the high side of expectations on very healthy sales.</li>    <li>Analysts expected a loss of 213M yuan; JD logged a 1B yuan profit (about $151M) on revenues that grew 39% Y/Y.</li>    <li>Gross profit rose 50% on a GAAP basis to 13B yuan (about $2B).</li>    <li>EBITDA from continuing operations more than doubled to 2.1B yuan (about $0.3B), with an EBITDA margin of 2.5%.</li>    <li>Revenue breakout: Online direct sales, 76.5B yuan (up 38.5%); Services and others, 7.28B yuan (up 46.2%).</li>    <li>For Q4, it's guiding to net revenues of 107B-110B yuan ($16.1B-$16.6B) -- a growth rate of 35-39% Y/Y, excluding the impact of JD Finance, and vs. expectations for 108.3B yuan.</li>    <li><a href=\"https://seekingalpha.com/pr/16999414-jd-com-announces-third-quarter-2017-results\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3311496\" data-linked=\"JD.com +4.7% after unexpected swing to profit on heavy sales\" data-tweet=\"$JD - JD.com +4.7% after unexpected swing to profit on heavy sales https://seekingalpha.com/news/3311496-jd-complus-4_7-after-unexpected-swing-to-profit-on-heavy-sales?source=tweet\" data-url=\"https://seekingalpha.com/news/3311496-jd-complus-4_7-after-unexpected-swing-to-profit-on-heavy-sales\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:50 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>24&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3311494\" data-ts=\"1510587386\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HES\" target=\"_blank\">HES</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3311494-hess-shuts-operations-three-gulf-of-mexico-fields-after-enchilada-fire\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Hess shuts operations at three Gulf of Mexico fields after Enchilada fire</a></h4><ul>     <li>Hess (<a href='https://seekingalpha.com/symbol/HES' title='Hess Corporation'>HES</a> <font color='red'>-1.6%</font>) says it has <a href=\"https://www.upi.com/Energy-News/2017/11/13/Some-Gulf-of-Mexico-operations-shut-in-after-fire/4551510579338/\" target=\"_blank\">shut down production</a> at three Gulf of Mexico oil fields following <a href=\"https://seekingalpha.com/news/3309926-shell-shuts-gulf-mexico-platforms-fire\" target=\"_blank\">last week's fire</a> at Royal Dutch Shell&rsquo;s (<a href='https://seekingalpha.com/symbol/RDS.A' title='Royal Dutch Shell plc'>RDS.A</a>, <a href='https://seekingalpha.com/symbol/RDS.B' title='Royal Dutch Shell plc'>RDS.B</a>) Enchilada platform.</li>     <li>Hess says it was told by Shell that a repair plan was being developed, but it was forced to halt production from the Baldpate, Conger and Penn State fields as a result.</li>     <li>Hess says its share of production from the fields is 30K boe/day, and that it is working with Shell to get a better sense of when operations could resume.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3311494\" data-linked=\"Hess shuts operations at three Gulf of Mexico fields after Enchilada fire\" data-tweet=\"$HES $HES $RDS.A - Hess shuts operations at three Gulf of Mexico fields after Enchilada fire https://seekingalpha.com/news/3311494-hess-shuts-operations-three-gulf-of-mexico-fields-after-enchilada-fire?source=tweet\" data-url=\"https://seekingalpha.com/news/3311494-hess-shuts-operations-three-gulf-of-mexico-fields-after-enchilada-fire\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:36 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3311491\" data-ts=\"1510586969\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SNPS\" target=\"_blank\">SNPS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3311491-synopsys-announces-new-automotive-partnership\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Synopsys announces new automotive partnership</a></h4><ul><li>Synopsys (NASDAQ:<a href='https://seekingalpha.com/symbol/SNPS' title='Synopsys, Inc.'>SNPS</a>) <a href=\"https://seekingalpha.com/pr/17000025-synopsys-cea-announce-partnership-develop-emulation-solutions-automotive-applications\" target=\"_blank\">announces</a> a new partnership with the French Alternative Energies and Atomic Energy Commission.</li><li>The partnership centers on Synopsys&rsquo; ZeBu Server-3 emulation solution for advancing automotive SoC and system design.</li><li>Three goals: validating complex auto systems with physical and cyber components, estimating power consumption online without compromising speed, and improving design reliability leveraging emulation speed and accuracy.</li><li>Financial terms not disclosed.</li><li>Synopsys shares are&nbsp;<font color='green'>up 0.55%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3311491\" data-linked=\"Synopsys announces new automotive partnership\" data-tweet=\"$SNPS - Synopsys announces new automotive partnership https://seekingalpha.com/news/3311491-synopsys-announces-new-automotive-partnership?source=tweet\" data-url=\"https://seekingalpha.com/news/3311491-synopsys-announces-new-automotive-partnership\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:29 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3311490\" data-ts=\"1510586943\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JACK\" target=\"_blank\">JACK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3311490-jakks-pacific-gains-amid-toy-sector-m-talk\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">JAKKS Pacific gains amid toy sector M&amp;A talk</a></h4><ul> <li>The merger talk around Mattel and Hasbro has helped drive up JAKKS Pacific (NASDAQ:<a href='https://seekingalpha.com/symbol/JACK' title='Jack In The Box Inc.'>JACK</a>) <font color='green'>3.85%</font> as investors gauge the impact on potential impact on pricing in the toy sector.</li> <li>Shares of JAKKS still trade near the bottom of their 52-week range of $2.40 to $7.45.</li> <li>Previously: <a href=\"https://seekingalpha.com/news/3311255-mattel-plus-13_5-percent-wsj-report-hasbro-takeover-approach\" target=\"_blank\">Mattel +13.5% on WSJ report of Hasbro takeover approach</a> (Nov. 10)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3311377-analysts-dive-hasbro-mattel-potential\" target=\"_blank\">Analysts dive in on Hasbro-Mattel potential</a> (Nov. 13)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3311490\" data-linked=\"JAKKS Pacific gains amid toy sector M&amp;A talk\" data-tweet=\"$JACK - JAKKS Pacific gains amid toy sector M&amp;A talk https://seekingalpha.com/news/3311490-jakks-pacific-gains-amid-toy-sector-m-talk?source=tweet\" data-url=\"https://seekingalpha.com/news/3311490-jakks-pacific-gains-amid-toy-sector-m-talk\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:29 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3311489\" data-ts=\"1510586800\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AFSI\" target=\"_blank\">AFSI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3311489-amtrust-down-4-after-bull-throws-in-towel\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AmTrust down more than 4% after bull throws in the towel</a></h4><ul><li>\"We have gone from seeing more potential for positive catalysts to seeing more potential for negative ones,\" says JMP analyst Matthew Carletti, downgrading to Market Perform from Market Outperform.</li><li>Among those negative catalysts would be a downgrade from A.M. Best - not a huge deal for the business, but a bad headline.</li><li>Carletti might turn bullish again were the company to show several quarters without adverse development and improved disclosure.</li><li>Source: Bloomberg</li><li><a href='https://seekingalpha.com/symbol/AFSI' title='AmTrust Financial Services, Inc.'>AFSI</a>&nbsp;<font color='red'>down 4.65%</font>&nbsp;today and&nbsp;<font color='red'>64%</font>&nbsp;YTD.</li></ul><div class=\"tiny-share-widget\" data-id=\"3311489\" data-linked=\"AmTrust down more than 4% after bull throws in the towel\" data-tweet=\"$AFSI - AmTrust down more than 4% after bull throws in the towel https://seekingalpha.com/news/3311489-amtrust-down-4-after-bull-throws-in-towel?source=tweet\" data-url=\"https://seekingalpha.com/news/3311489-amtrust-down-4-after-bull-throws-in-towel\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:26 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>14&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3311485\" data-ts=\"1510586433\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CMG\" target=\"_blank\">CMG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3311485-chipotle-falls-after-actor-blames-for-hospital-trip\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Chipotle falls after actor blames it for hospital trip</a></h4><ul> <li>Chipotle (NYSE:<a href='https://seekingalpha.com/symbol/CMG' title='Chipotle Mexican Grill, Inc.'>CMG</a>) is <font color='red'>down 2.8%</font> on elevated volume after actor Jeremy Jordan blames his <a href=\"http://people.com/food/jeremy-jordan-chipotle-food-poisoning-hospital/\" target=\"_blank\">trip</a> to the hospital emergency room for stomach issues on the restaurant chain.</li> <li>Chipotle says it's investigating the claim, but can't confirm any link at this time.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3311485\" data-linked=\"Chipotle falls after actor blames it for hospital trip\" data-tweet=\"$CMG - Chipotle falls after actor blames it for hospital trip https://seekingalpha.com/news/3311485-chipotle-falls-after-actor-blames-for-hospital-trip?source=tweet\" data-url=\"https://seekingalpha.com/news/3311485-chipotle-falls-after-actor-blames-for-hospital-trip\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:20 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>39&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3311483\" data-ts=\"1510586237\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SGYP\" target=\"_blank\">SGYP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3311483-synergy-pharmaceuticals-prices-equity-offering-shares-down-7\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Synergy Pharmaceuticals prices equity offering; shares down 7%</a></h4><ul><li>Synergy Pharmaceuticals (<a href='https://seekingalpha.com/symbol/SGYP' title='Synergy Pharmaceuticals, Inc.'>SGYP</a> <font color='red'>-7%</font>) <a href=\"https://seekingalpha.com/pr/17000050-synergy-pharmaceuticals-announces-pricing-offering-common-stock-warrants\" target=\"_blank\">prices </a>its public offering of ~21.7M shares of common stock and accompanying warrants at $2.58 per share and warrant. Gross proceeds should be ~$56M. Closing date is November 15.</li><li>Each warrant is exercisable at $2.86 per common share.</li></ul><div class=\"tiny-share-widget\" data-id=\"3311483\" data-linked=\"Synergy Pharmaceuticals prices equity offering; shares down 7%\" data-tweet=\"$SGYP $SGYP-OLD - Synergy Pharmaceuticals prices equity offering; shares down 7% https://seekingalpha.com/news/3311483-synergy-pharmaceuticals-prices-equity-offering-shares-down-7?source=tweet\" data-url=\"https://seekingalpha.com/news/3311483-synergy-pharmaceuticals-prices-equity-offering-shares-down-7\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:17 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>106&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3311482\" data-ts=\"1510585507\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LKM\" target=\"_blank\">LKM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3311482-nq-mobile-sets-150m-buyback-of-shares-convertible-notes\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">NQ Mobile sets $150M buyback of shares, convertible notes</a></h4><ul>   <li>NQ Mobile (NQ) is <font color='green'>up 1.9%</font> in early going after authorizing a <a href=\"https://seekingalpha.com/pr/16999864-nq-mobile-inc-announces-board-directors-authorized-us-150-million-buyback-program-shares\" target=\"_blank\">buyback program of up to $150M</a> of its shares or convertible notes.</li>    <li>That program covers the next 12 months and allows for purchase on the open market as well private transactions and block trades.</li>    <li>The buybacks will be funded from cash on hand; in its <a href=\"https://seekingalpha.com/news/3256050-nq-mobile-minus-9_1-percent-amid-swing-loss-fiscal-q4\" target=\"_blank\">April report</a>, the company reported $318.2M in cash, equivalents, term deposits and restricted cash.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3311482\" data-linked=\"NQ Mobile sets $150M buyback of shares, convertible notes\" data-tweet=\"$LKM - NQ Mobile sets $150M buyback of shares, convertible notes https://seekingalpha.com/news/3311482-nq-mobile-sets-150m-buyback-of-shares-convertible-notes?source=tweet\" data-url=\"https://seekingalpha.com/news/3311482-nq-mobile-sets-150m-buyback-of-shares-convertible-notes\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:05 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3311473\" data-ts=\"1510584950\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CNIT-OLD\" target=\"_blank\">CNIT-OLD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3311473-china-information-technology-up-after-reporting-nine-month-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">China Information Technology up after reporting nine-month results</a></h4><ul><li>        China Information Technology (NASDAQ:<a href='https://seekingalpha.com/symbol/CNIT-OLD' title='China Information Technology'>CNIT-OLD</a>) shares are&nbsp;<font color='green'>up 7.12%</font>&nbsp;after the company reports results for the first nine months of this year.</li><li>               Revenue was $12.2M, up 97% on the same period last year. EPS was $0.03 compared to the -$0.25 last year.&nbsp;</li><li>               The company ended the period with $1.8M in cash and equivalents and $7.5M in short-term debt.&nbsp;</li><li>               <a href=\"https://seekingalpha.com/filing/3762072\" target=\"_blank\">Earnings results </a>&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3311473\" data-linked=\"China Information Technology up after reporting nine-month results\" data-tweet=\"$CNIT-OLD - China Information Technology up after reporting nine-month results https://seekingalpha.com/news/3311473-china-information-technology-up-after-reporting-nine-month-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3311473-china-information-technology-up-after-reporting-nine-month-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:55 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3311468\" data-ts=\"1510584533\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NKTR\" target=\"_blank\">NKTR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3311468-combination-of-opdivo-and-nektars-nktrminus-214-show-positive-effect-in-advanced-lung-cancer\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Combination of Opdivo and Nektar&#39;s NKTR-214 show positive effect in advanced lung cancer in Phase 1/2 study</a></h4><ul><li>Nektar Therapeutics (<a href='https://seekingalpha.com/symbol/NKTR' title='Nektar Therapeutics'>NKTR</a> <font color='green'>+25.6%</font>) <a href=\"https://seekingalpha.com/pr/16999261-first-data-nktrminus-214-combination-opdivo-nivolumab-patients-stage-iv-melanoma-renal-cell\" target=\"_blank\">reported </a>more good news on therapeutic cancer vaccine candidate NKTR-214 at the SITC Annual Meeting in National Harbor, MD.</li><li>In the dose-escalation portion of a Phase 1/2 trial, PIVOT, the combination of NKTR-214 and Bristol-Myers Squibb's (<a href='https://seekingalpha.com/symbol/BMY' title='Bristol-Myers Squibb Company'>BMY</a> <font color='red'>-0.1%</font>) Opdivo (nivolumab) produced responses in three of four patients with Stage IV non-small cell lung cancer whose tumors did not express PD-L1 and who had progressed after prior treatment with chemo. There was one complete responder.</li><li>In melanoma patients, the response rate was 63% (n=7/11), including one complete responder.</li><li>In late-stage renal cell carcinoma patients with at least one baseline scan, the response rate was 46% and the disease control rate was 85%</li><li>The Phase 2 portion is currently enrolling patients across five different tumor types.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3311415-nektar-therapeutics-25-percent-premarket-encouraging-preclinical-data-immune-system\" target=\"_blank\">Nektar Therapeutics up 25% premarket on encouraging preclinical data on immune system stimulator NKTR-214</a> (Nov. 13)</li></ul><div class=\"tiny-share-widget\" data-id=\"3311468\" data-linked=\"Combination of Opdivo and Nektar&#39;s NKTR-214 show positive effect in advanced lung cancer in Phase 1/2 study\" data-tweet=\"$NKTR $NKTR $BMY - Combination of Opdivo and Nektar&#39;s NKTR-214 show positive effect in advanced lung cancer in Phase 1/2 study https://seekingalpha.com/news/3311468-combination-of-opdivo-and-nektars-nktrminus-214-show-positive-effect-in-advanced-lung-cancer?source=tweet\" data-url=\"https://seekingalpha.com/news/3311468-combination-of-opdivo-and-nektars-nktrminus-214-show-positive-effect-in-advanced-lung-cancer\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:48 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3311471\" data-ts=\"1510584343\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMT\" target=\"_blank\">AMT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3311471-american-tower-boosts-india-presence-1_2b-site-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">American Tower boosts India presence with $1.2B site deal</a></h4><ul>   <li>American Tower (<a href=\"http://seekingalpha.com/symbol/AMT\" target=\"_blank\">AMT</a> <font color='green'>+0.5%</font>) has raised its infrastructure presence in India by a third, with a <a href=\"https://www.bloomberg.com/news/articles/2017-11-13/american-tower-to-buy-vodafone-idea-units-for-1-2-billion\" target=\"_blank\">deal to pay 78.5B rupees</a> (about $1.2B) for some 20,000 towers from Idea Cellular and Vodafone (<a href=\"http://seekingalpha.com/symbol/VOD\" target=\"_blank\">VOD</a> <font color='red'>-1.9%</font>).</li>    <li>That move comes as Idea and Vodafone's India business get set to merge, and begin selling off assets for debt repayment.</li>    <li>American Tower's deal is expected to close in the first half of next year, and generate about $320M in property revenue and $120M in gross profits for the first full year.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3311471\" data-linked=\"American Tower boosts India presence with $1.2B site deal\" data-tweet=\"$AMT $AMT $VOD - American Tower boosts India presence with $1.2B site deal https://seekingalpha.com/news/3311471-american-tower-boosts-india-presence-1_2b-site-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3311471-american-tower-boosts-india-presence-1_2b-site-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:45 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3311470\" data-ts=\"1510584220\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMZN\" target=\"_blank\">AMZN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3311470-morgan-stanley-analyst-outlines-1t-amazon-bull-case\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Morgan Stanley analyst outlines $1T Amazon bull case</a></h4><ul><li>        Morgan Stanley <a href=\"https://www.cnbc.com/2017/11/13/morgan-stanley-amazon-could-be-1-trillion-company-within-a-year.html\" target=\"_blank\">reiterates</a> its Overweight rating for Amazon (NASDAQ:<a href='https://seekingalpha.com/symbol/AMZN' title='Amazon.com, Inc.'>AMZN</a>) and presents a $2K per share bull case that would give the e-commerce giant a $1T market cap.</li><li>               Analyst Brian Nowak cites the company&rsquo;s high margins and the forward performance of five segments: first-party ((1P)), third-party ((3P)), AWS, Subscription, and Advertising/Other as the tailwinds for the bull case.&nbsp;</li><li>               Nowak&rsquo;s math is based on estimating sales growth for each of the key segments up to 2022. His estimates put the core 1P business at $600B and AWS at $270B.&nbsp;</li><li>               Amazon shares are&nbsp;<font color='green'>up 0.38%</font>&nbsp;to $1,129.60.&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3311470\" data-linked=\"Morgan Stanley analyst outlines $1T Amazon bull case\" data-tweet=\"$AMZN - Morgan Stanley analyst outlines $1T Amazon bull case https://seekingalpha.com/news/3311470-morgan-stanley-analyst-outlines-1t-amazon-bull-case?source=tweet\" data-url=\"https://seekingalpha.com/news/3311470-morgan-stanley-analyst-outlines-1t-amazon-bull-case\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:43 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>25&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3311469\" data-ts=\"1510584141\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BAM\" target=\"_blank\">BAM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3311469-mall-names-mostly-higher-after-brookfield-bid-for-ggp-made-official\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Mall names mostly higher after Brookfield bid for GGP made official</a></h4><ul><li>Brookfield Asset Management's (<a href='https://seekingalpha.com/symbol/BAM' title='Brookfield Asset Management Inc.'>BAM</a> <font color='green'>+0.3%</font>) Brookfield Property Partners (<a href='https://seekingalpha.com/symbol/BPY' title='Brookfield Property Partners L.P.'>BPY</a> <font color='red'>-5.2%</font>) is offering GGP owners <a href=\"https://seekingalpha.com/pr/16999741-brookfield-property-partners-l-p-proposes-acquire-b-ggp-b-inc-23_00-per-share-combination\" target=\"_blank\">$23 in cash or </a>0.9656 BPY units for each share of GGP they hold.</li><li>Maximum cash consideration will be $7.4B (50% of the total offer). The deal works out to a 21% premium to GGP's share price prior to the first stories of Brookfield's interest hitting the papers last week.</li><li>GGP <a href=\"https://seekingalpha.com/pr/16999763-ggp-inc-confirms-receipt-unsolicited-proposal-brookfield-property-partners-l-p\" target=\"_blank\">has acknowledged</a> receipt of the offer, and is having a look.</li><li>GGP is&nbsp;&nbsp;<font color='green'>higher by 7.2%&nbsp;</font>to $23.80.</li><li>Simon Property (<a href='https://seekingalpha.com/symbol/SPG' title='Simon Property Group, Inc.'>SPG</a> <font color='red'>-0.2%</font>), Taubman Centers (<a href='https://seekingalpha.com/symbol/TCO' title='Taubman Centers, Inc.'>TCO</a> <font color='green'>+4.1%</font>), Brixmor (<a href='https://seekingalpha.com/symbol/BRX' title='Brixmor Property Group Inc.'>BRX</a> <font color='green'>+0.5%</font>), Kimco (<a href='https://seekingalpha.com/symbol/KIM' title='Kimco Realty Corporation'>KIM</a> <font color='green'>+1%</font>), Weingarten (<a href='https://seekingalpha.com/symbol/WRI' title='Weingarten Realty Investors'>WRI</a> <font color='green'>+0.6%</font>), Macerich (<a href='https://seekingalpha.com/symbol/MAC' title='Macerich Co.'>MAC</a> <font color='green'>+1%</font>), DDR (DDR <font color='green'>+1.6%</font>)</li></ul><div class=\"tiny-share-widget\" data-id=\"3311469\" data-linked=\"Mall names mostly higher after Brookfield bid for GGP made official\" data-tweet=\"$BAM $BAM $BPY - Mall names mostly higher after Brookfield bid for GGP made official https://seekingalpha.com/news/3311469-mall-names-mostly-higher-after-brookfield-bid-for-ggp-made-official?source=tweet\" data-url=\"https://seekingalpha.com/news/3311469-mall-names-mostly-higher-after-brookfield-bid-for-ggp-made-official\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:42 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3311461\" data-ts=\"1510583147\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TI\" target=\"_blank\">TI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3311461-telecom-italiaminus-2_8-goldman-cuts-to-neutral\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Telecom Italia -2.8% as Goldman cuts to Neutral</a></h4><ul>   <li>Telecom Italia (NYSE:<a href='https://seekingalpha.com/symbol/TI' title='Telecom Italia S.P.A.'>TI</a>) is <font color='red'>2.8% lower</font> in premarket U.S. trading after a cut to Neutral at Goldman Sachs.</li>    <li>Analyst Andrew Lee has a price target of &euro;0.86; implying 24% upside from a newly lower price in Italy (shares are <font color='red'>down 3%</font> in Milan to &euro;0.692).</li>    <li>Shares on NYSE are <font color='green'>up 5%</font> YTD.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3311461\" data-linked=\"Telecom Italia -2.8% as Goldman cuts to Neutral\" data-tweet=\"$TI - Telecom Italia -2.8% as Goldman cuts to Neutral https://seekingalpha.com/news/3311461-telecom-italiaminus-2_8-goldman-cuts-to-neutral?source=tweet\" data-url=\"https://seekingalpha.com/news/3311461-telecom-italiaminus-2_8-goldman-cuts-to-neutral\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:25 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3311460\" data-ts=\"1510583048\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EFX\" target=\"_blank\">EFX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3311460-equifax-loses-sell-side-bull-shares-down-2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Equifax loses sell-side bull; shares down 2%</a></h4><ul><li>via Bloomberg</li><li>Stifel's&nbsp;Shlomo Rosenbaum sees \"very muted\" growth next year as the company will be spending its energies on rebuilding confidence following the cyberattack.</li><li>If they can get past the near-term \"dead money,\" longer-term investors could still find the stock attractive, he says.</li><li>Rosenbaum downgrades to Hold from Buy, and cuts the price target to $115 from $149. <a href='https://seekingalpha.com/symbol/EFX' title='Equifax Inc.'>EFX</a>&nbsp;<font color='red'>-2.05%</font>&nbsp;premarket to $106.50.</li></ul><div class=\"tiny-share-widget\" data-id=\"3311460\" data-linked=\"Equifax loses sell-side bull; shares down 2%\" data-tweet=\"$EFX - Equifax loses sell-side bull; shares down 2% https://seekingalpha.com/news/3311460-equifax-loses-sell-side-bull-shares-down-2?source=tweet\" data-url=\"https://seekingalpha.com/news/3311460-equifax-loses-sell-side-bull-shares-down-2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:24 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3311459\" data-ts=\"1510583040\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TRXC\" target=\"_blank\">TRXC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3311459-transenterix-books-first-u-s-order-for-senhance-robotic-system-shares-ahead-16-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">TransEnterix books first U.S. order for Senhance Robotic System; shares ahead 16% premarket</a></h4><ul><li>Transenterix (NYSEMKT:<a href='https://seekingalpha.com/symbol/TRXC' title='TransEnterix, Inc.'>TRXC</a>) is up&nbsp;<font color='green'>16%</font>&nbsp;premarket on robust volume on the heels its <a href=\"https://seekingalpha.com/pr/16999870-transenterix-announces-senhance-us-sale-agreement-florida-hospital\" target=\"_blank\">announcement </a>that Orlando-based Florida hospital has ordered the Senhance Surgical Robotic System, the first in the U.S.</li><li>The FDA cleared the device in October.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3301042-fda-clears-tranenterixs-robotic-surgery-system-senhance-shares-ahead-60-percent-hours\" target=\"_blank\">FDA clears TranEnterix's robotic surgery system Senhance; shares ahead 60% after hours</a> (Oct. 13)</li></ul><div class=\"tiny-share-widget\" data-id=\"3311459\" data-linked=\"TransEnterix books first U.S. order for Senhance Robotic System; shares ahead 16% premarket\" data-tweet=\"$TRXC - TransEnterix books first U.S. order for Senhance Robotic System; shares ahead 16% premarket https://seekingalpha.com/news/3311459-transenterix-books-first-u-s-order-for-senhance-robotic-system-shares-ahead-16-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3311459-transenterix-books-first-u-s-order-for-senhance-robotic-system-shares-ahead-16-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:24 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>25&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3311455\" data-ts=\"1510582579\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ALNY\" target=\"_blank\">ALNY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3311455-european-advisory-group-grants-accelerated-review-for-alnylams-patisiran-for-hattr\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">European advisory group grants accelerated review for Alnylam&#39;s patisiran for hATTR amyloidosis; shares up 1% premarket</a></h4><ul><li>The European Medicines Agency's Committee for Medicinal Products for Human Use &#40;CHMP&#41; <a href=\"https://seekingalpha.com/pr/16999580-european-medicines-agency-ema-grants-alnylam-accelerated-assessment-patisiran-patients\" target=\"_blank\">grants </a>accelerated assessment of Alnylam Pharmaceuticals' (NASDAQ:<a href='https://seekingalpha.com/symbol/ALNY' title='Alnylam Pharmaceuticals, Inc.'>ALNY</a>) marketing application seeking approval for patisiran for the treatment of hereditary ATTR (hATTR) amyloidosis.</li><li>Accelerated assessment status shortens the review clock to 150 days from the usual 210 days.</li><li>The company expects to file its Marketing Authorization Application by year-end.</li><li>Shares are up&nbsp;<font color='green'>1%</font>&nbsp;premarket but only on 250 shares.</li></ul><div class=\"tiny-share-widget\" data-id=\"3311455\" data-linked=\"European advisory group grants accelerated review for Alnylam&#39;s patisiran for hATTR amyloidosis; shares up 1% premarket\" data-tweet=\"$ALNY - European advisory group grants accelerated review for Alnylam&#39;s patisiran for hATTR amyloidosis; shares up 1% premarket https://seekingalpha.com/news/3311455-european-advisory-group-grants-accelerated-review-for-alnylams-patisiran-for-hattr?source=tweet\" data-url=\"https://seekingalpha.com/news/3311455-european-advisory-group-grants-accelerated-review-for-alnylams-patisiran-for-hattr\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:16 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3311454\" data-ts=\"1510582473\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3311454-premarket-gainers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Gainers as of 9:05 am</a></h4><ul>     <li><a href='https://seekingalpha.com/symbol/NKTR' title='Nektar Therapeutics'>NKTR</a> <font color='green'>+27%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3311415-nektar-therapeutics-25-percent-premarket-encouraging-preclinical-data-immune-system\" target=\"_blank\">positive</a> preclinical data on immune system stimulator NKTR-214.</li>     <li><a href='https://seekingalpha.com/symbol/MAT' title='Mattel, Inc.'>MAT</a> <font color='green'>+22%</font>.</li>     <li><a href='https://seekingalpha.com/symbol/EKSO' title='Ekso Bionics Holdings, Inc.'>EKSO</a> <font color='green'>+16%</font>.</li>     <li><a href='https://seekingalpha.com/symbol/TRXC' title='TransEnterix, Inc.'>TRXC</a> <font color='green'>+11%</font>&nbsp;on <a href=\"https://seekingalpha.com/pr/16999870-transenterix-announces-senhance-us-sale-agreement-florida-hospital\" target=\"_blank\">announcement</a> that Florida Hospital entered into an agreement to purchase the Company&rsquo;s Senhance&trade; Surgical Robotic System.</li>     <li><a href='https://seekingalpha.com/symbol/CNIT-OLD' title='China Information Technology'>CNIT-OLD</a> <font color='green'>+8%</font>.</li>     <li><a href='https://seekingalpha.com/symbol/QD' title='Qudian, Inc.'>QD</a> <font color='green'>+8%</font>&nbsp;on Q3 <a href=\"https://seekingalpha.com/news/3311321-qudian-reports-q3-results\" target=\"_blank\">result</a>.</li>     <li>GGP <font color='green'>+7%</font>&nbsp;on offer by&nbsp;&nbsp;Brookfield Asset Management (NYSE:<a href='https://seekingalpha.com/symbol/BAM' title='Brookfield Asset Management Inc.'>BAM</a>).</li>     <li><a href='https://seekingalpha.com/symbol/DFFN' title='Diffusion Pharmaceuticals Inc.'>DFFN</a> <font color='green'>+6%</font>&nbsp;on Q3 <a href=\"https://seekingalpha.com/news/3311405-diffusion-pharmaceuticals-reports-q3-results\" target=\"_blank\">result</a>.</li>     <li><a href='https://seekingalpha.com/symbol/CAPR' title='Capricor Therapeutics, Inc.'>CAPR</a> <font color='green'>+6%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3311454\" data-linked=\"Premarket Gainers as of 9:05 am\" data-tweet=\"$NKTR $MAT $EKSO - Premarket Gainers as of 9:05 am https://seekingalpha.com/news/3311454-premarket-gainers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3311454-premarket-gainers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:14 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3311448\" data-ts=\"1510582107\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3311448-premarket-losers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Losers as of 9:05 am</a></h4><ul>     <li><a href='https://seekingalpha.com/symbol/VRAY' title='ViewRay'>VRAY</a>&nbsp;<font color='red'>-9%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3311349-viewray-misses-0_07-misses-revenue\" target=\"_blank\">Q3 result</a>.</li><li><a href='https://seekingalpha.com/symbol/JP' title='Jupai Holdings'>JP</a>&nbsp;<font color='red'>-8%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3311318-jupai-holdings-reports-q3-results\" target=\"_blank\">Q3 result</a>.</li><li>ONP <font color='red'>-5%</font>.</li><li><a href='https://seekingalpha.com/symbol/GNCA' title='Genocea Biosciences, Inc.'>GNCA</a> <font color='red'>-5%</font>.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3311448\" data-linked=\"Premarket Losers as of 9:05 am\" data-tweet=\"$VRAY $JP $ITP - Premarket Losers as of 9:05 am https://seekingalpha.com/news/3311448-premarket-losers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3311448-premarket-losers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:08 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3311445\" data-ts=\"1510581968\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PLX\" target=\"_blank\">PLX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3311445-european-advisory-group-backs-orphan-drug-status-for-protalix-bios-fabry-candidate-prxminus\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">European advisory group backs Orphan Drug status for Protalix Bio&#39;s Fabry candidate PRX-102; shares ahead 5% premarket</a></h4><ul><li>Nano cap Protalix BioTherapeutics (NYSEMKT:<a href='https://seekingalpha.com/symbol/PLX' title='Protalix BioTherapeutics, Inc'>PLX</a>) perks up&nbsp;<font color='green'>5%</font>&nbsp;premarket on increased volume in response to its <a href=\"https://seekingalpha.com/pr/16999503-protalix-biotherapeutics-receives-positive-opinion-orphan-designation-prxminus-102-treatment\" target=\"_blank\">announcement </a>that the European Medicines Agency's Committee for Orphan Medicinal Products &#40;COMP&#41; has issued a positive opinion recommending Orphan Drug status for PRX-102 (pegunigalsidase alfa) for the treatment of Fabry disease.</li><li>Among the benefits of Orphan Drug status in Europe is a 10-year period of market exclusivity for the indication, if approved.</li></ul><div class=\"tiny-share-widget\" data-id=\"3311445\" data-linked=\"European advisory group backs Orphan Drug status for Protalix Bio&#39;s Fabry candidate PRX-102; shares ahead 5% premarket\" data-tweet=\"$PLX - European advisory group backs Orphan Drug status for Protalix Bio&#39;s Fabry candidate PRX-102; shares ahead 5% premarket https://seekingalpha.com/news/3311445-european-advisory-group-backs-orphan-drug-status-for-protalix-bios-fabry-candidate-prxminus?source=tweet\" data-url=\"https://seekingalpha.com/news/3311445-european-advisory-group-backs-orphan-drug-status-for-protalix-bios-fabry-candidate-prxminus\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:06 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li>","count":75,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}